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Summary
Recent investigations imply that a key mechanism in the 
pathogenesis of periodontal disease may be the ability of 
oral micro-organisms to induce production and /or activation 
of matrix metalloproteinases in the host tissues.
Stromelysin (SL) is a member of the matrix metalloproteinase 
family which may play a role in chronic inflammatory 
periodontitis. Extracellular control of these enzymes is 
performed by tissue inhibitor of metalloproteinases (TIMP) 
and during normal tissue turnover, inflammation and healing, 
levels of MMPs and TIMP will change.
The effect of treatment on the levels of MMPs and inhibitors 
has been to decrease collagenase activity, to decrease the 
amount of collagenase and stromelysin (SL) produced, and to 
increase the level of TIMP.
It has been suggested that the pharmacologic inhibition of 
MMP activity could play an important role in achieving a 
desirable outcome in periodontal therapy. In addition to 
antimicrobial effects, tetracyclines have been shown to be 
able to inhibit metalloproteinases (MMPs). However, recent 
results indicate that the inhibition of MMPs by systemic 
tetracycline depends on the drug concentration and type as 
well as the origin of the MMP. Therefore, theoretically a 
greater inhibitory effect on MMPs would be expected if higher 
concentrations of drug could be delivered to the site of
XIX
action. Recently, there has been increasing interest in the 
use of locally delivered antibiotics in order to obtain a 
high concentration of the drug at the target site and to 
minimise potential systemic adverse effects. We therefore 
sought to investigate the efficacy of locally delivered 
antibiotics on the level of gingival crevicular fluid (GCF) 
stromelysin (SL) and tissue inhibitor of metalloproteinases 
((TIMP) on sites with a history of a poor response to 
mechanical treatment.
52 patients with 4 periodontal pockets >5 mm and bleeding on 
probing were randomised into four groups of 13 patients. One 
group received scaling and root planing alone and the other 
three groups received scaling and root planing plus a locally 
delivered antimicrobial system. These included 25%
tetracycline fibre, 2% minocycline gel, and 25% metronidazole 
gel. The GCF samples taken at baseline and 6 weeks after 
treatments were analysed using an enzyme linked immunosorbent 
assay (ELISA).
All treatments resulted in significant improvement in 
clinical parameters. The pocket depth reduction was 
significantly greater in the scaling plus tetracycline fibre 
group than the scaling alone group (p=0.003). GCF SL levels 
significantly decreased after adjunctive tetracycline fibre 
(paired t-test, p=0.020) and minocycline gel (paired t-test, 
p=0.023) treatments whereas it remained almost unchanged in 
the other two groups. While the GCF TIMP level did not 
change significantly in the scaling and root planing alone
XX
group, it significantly increased for all three adjunctive 
antimicrobial treatments (for tetracycline fibre p<0.001, 
minocycline gel p=0.005, metronidazole gel p<0.001). The 
analysis of covariance (ANCOVA) on the baseline SL was used 
to reduce the error resulting from the variation in the 
baseline. The level of SL at baseline had a significant 
effect on the SL change following treatment (p<0.001), and 
this effect was positive i.e. the higher the baseline SL, the 
higher the reduction of SL. Treatment also had a significant 
effect on the reduction of SL (p=0.001). Follow-up analysis 
showed significant differences between; i) tetracycline fibre 
plus scaling and scaling alone groups (p=0.004); and ii) 
minocycline gel plus scaling and scaling alone groups 
((p-0 . 002) .
There was a significant difference in TIMP levels between 
treatment groups (p=0.007). Furthermore, the analysis of 
TIMP levels revealed that a significant difference existed 
between the minocycline gel plus scaling and the scaling 
alone group (p=0.018), and also between the metronidazole gel 
plus scaling and the scaling alone group (p=0.001).
Our observation that the mean level of SL decreased after 
antibiotic treatment could be explained by the fact that 
local delivery of antibiotics plus scaling and root planing 
may change the microbial flora. This may cause a larger 
decrease of SL than scaling and root planing alone. However, 
the greatest decrease was observed in the sites treated by 
tetracycline or minocycline delivery systems.
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Previous studies have also shown that tetracyclines, in 
addition to decreasing the level of periodontal bacteria, 
resulting in decrease of MMP activity in the gingiva, could 
decrease the synthesis of pro-MMPs and also protect the 
endogenous MMP inhibitors (TIMP-1) and other proteinase 
inhibitors (al-antitrypsin) from degradation and 
inactivation by direct and indirect mechanisms. However, it 
cannot be established from this study whether the effect of 
the tetracyclines on the level of SL is direct, or indirect 
through the reduction in microbial challenge which could 
reduce the microbial proteases and inflammatory mediators 
such as cytokines, both of which could reduce the levels of 
human MMP. After treatment the level of free TIMP increased. 
This might be due to a reduction in MMPs which would bind 
to free TIMP. The elevation of GCF TIMP was higher in the 
metronidazole group than in the other groups. This indicates 
that the regulation of TIMP is not solely dependent on the 
MMPs. The observation of a greater clinical improvement in 
all three adjunctive antimicrobial treatment groups compared 
with the scaling and root planing alone supports our 
biochemical findings and suggests that the extent of healing 
in the patients who received local delivery antibiotics was 
greater than the group who only received scaling and root 
planing. The use of adjunctive locally delivered
antimicrobial systems, particularly, the tetracycline family, 
may offer an advantage in changing the metalloproteinase 
profile of the GCF to a one more compatible with periodontal 
health.
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CHAPTER 1 
INTRODUCTION
1.1 The 'Normal' periodontium; Clinical and 
histological features
The periodontium known collectively as the supporting 
tissues of the teeth (from the Greek, Peri, around, and 
Odonts, tooth), are comprised of the gingivae, the 
periodontal ligament, the root cementum, and the alveolar 
bone (Lindhe, 1989).
In normal periodontium, the gingivae are pale pink in 
colour, scalloped in outline, have a firm consistency, does 
not bleed on gentle probing and terminate coronally in a 
knife-edge relationship with the tooth surface (Wennstrom, 
1988) . Histologically, no inflammatory exudate is found 
and only a few neutrophilic granulocytes can be detected 
within the epithelium immediately adjacent to the tooth 
surface (Schluger, 1990); the alveolar bone is located 1 mm 
apical to the cemento-enamel junction (Eliasson et al. , 
1986)
1.2 Periodontal disease; clinical and
histological features
The term 'periodontal disease7 , if used in the general 
sense, includes all the pathological conditions of the 
periodontium. Its usage is controversial, because of the
1
heterogeneity of the disease, and its multifactorial 
aetiology.
However, in this text, the term periodontal disease will 
only be used to refer to refractory disease. The clinical 
symptoms of periodontal disease comprise: a) redness and
swelling of the gingivae; b) increased tendency to bleeding 
on probing the gingival sulcus/pocket; c) reduced 
resistance to probing; d) tissue recession; e) reduced 
height of the alveolar bone which is seen on the 
radiograph; f) mobility and drifting of the teeth which 
appears in the advanced stages of the disease.
1.3 Recent concepts in the epidemiology of
periodontal disease
The epidemiologic approach to the study of periodontal 
disease was begun several decades ago. Early studies, were 
concerned with the discovery of the prevalence and extent 
of periodontal disease in populations and groups of 
individuals. Results of these studies, have shown that the- 
prevalence and extent of disease increases with increasing 
age. The earliest study on the prevalence of periodontitis 
in humans was performed by Black in 1918. It was reported 
that loss of teeth from periodontal disease began at 
approximately 3 5 years of age, and the rate climbed
2
geometrically thereafter. Hughes et al. (1982)
demonstrated that the proportions of white women and men 
with periodontitis were 10.8% and 13.5% respectively 
whereas the values for non-white women and men were 22.3% 
and 32.4%. Hughes et al. therefore concluded, that the 
prevalence and severity of periodontitis increased with 
advancing age, were greater for non-whites than for whites, 
and were greater in man of both races than in women.
Schenkein et al. (1993) failed to show significant 
differences between the composition of the subgingival 
flora in males and females. The results of a 5 year 
clinical trial of 1,426 subjects, which was conducted to 
evaluate the relationship of the periodontal microflora, 
demographic finding, and clinical data to periodontal 
disease (Grossi et al., 1994) demonstrated that the
prevalence of the target periodontal pathogens was greater 
in males than in females. Furthermore, the African- 
Americans were more often infected with target species than 
white. However, the prevalence of target periodontal 
pathogens based on species was different in different age 
groups. This study also showed that subjects in younger 
age categories were at lower risk of clinical attachment 
loss. They also showed that the risk of attachment loss 
was greater in males compared to females. Abdellatif & 
Burt (1987) suggested that while the prevalence of 
periodontitis may increase with age, age alone in a healthy
3
adult does not lead to progression of periodontal disease. 
Therefore, it can also be concluded that age may correlate 
rather than be a risk factor for periodontal destruction. 
Moreover, in smokers, depending on whether the subjects 
were judged to be light, moderate, or heavy smokers, there 
is a greater risk of attachment loss in a dose dependent 
manner. It has also been shown that the risk of attachment 
loss increased in molars than premolars or anteriors (Loos 
et al., 1989; Nordland et al., 1987). In addition, Brayer
et al. (1989) and Fleischer et al. (1989) reported that
molars become calculus-free less often than single-rooted
teeth. Thus, the poor response to the treatment in molars
can be due to difficulty in removal of calculus in molars 
than other teeth.
1.4 Pathogenesis and progression of periodontal
disease
Periodontal diseases are now recognised as being mixed 
bacterial infections of the supporting tissues of the teeth 
(Socransky & Haffajee, 1991). A variety of pathogenic 
mechanisms and virulence factors are involved in the 
periodontopathic potential of organisms implicated in 
periodontal disease. However, Socransky & Haffajee (1991) 
reported that various forms of periodontal diseases are 
closely associated with specific subgingival bacteria. As
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early as 1907, Goadby presumed that bacteria invade oral 
tissue. Several years later, Ray and Orban (1948) 
hypothesised that the necrosis of tissue in gingival biopsy 
samples was caused by bacterial invasion. During the 1960s 
and 1970s, again, investigators identified different 
bacteria and attempted to relate them to different 
periodontal diseases. Saglie & Elbaz (1983) found that 
bacterial invasion of soft periodontal tissue and bone was 
common in advanced periodontitis and localised juvenile 
periodontitis. They also reported that bacteria invade the 
epithelial wall and are formed, in the enlarged 
intracellular spaces of the pocket epithelial surface, on 
the epithelial side of the basal lamina, and in the 
connective tissue. In subsequent studies, it was found 
that the organised accumulation of micro-organisms at the 
tooth surface triggers humoral and cellular mechanisms of 
host defence (Williams, 1990). Microbial release of 
chemotactic factors, endotoxins, cell wall fragments, 
toxins, and other products activate leukocyte populations 
that emigrate from the vasculature, and attempt to 
eradicate the offending pathogens (Williams, 1990). While 
these events are characteristic of the host response to 
injury, bacteria, or antigen deposition, the inability of 
the host to eliminate or sequester persistently 
accumulating numbers of pathogens that occur in the oral 
cavity results in prolonged inflammation. This progression 
to chronic periodontal disease may be associated with the
5
destruction of soft tissue and alveolar bone (Williams, 
1990) . PMNs play a key role in the immune response and 
form the first line of defence in the gingival sulcus 
against periodontal bacteria. Quantitative (neutropenia) 
and qualitative (chemotactic or phagocytic) PMN 
deficiencies have been shown to have an important role in 
severe periodontal destruction (Wilton et al., 1988; Kinane 
& Davies, 1990). Understanding the sequence of events of 
the progression to pathologic tissue injury is important in 
the identification of targets for modulating chronic 
inflammatory processes as an adjunct to antimicrobial 
therapy.
Three transient models have been proposed to describe the 
progression of periodontitis (Socransky et al., 1984). The 
continuous model suggested that the destruction of tooth 
supporting tissue proceeds in long periods of slow and 
constant activity with few periods of quiescence. The 
random or episodic burst model proposes a number of 
relatively short periods in which severe destruction is 
followed by remission and quiescence. The multiple 
asynchronous burst model postulates that the majority of 
periodontal destruction occurs during a defined period of 
life, and then disease activity remains essentially 
quiescent thereafter.
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1.5 The features of destruction in periodontitis
The development of the host response and histopathogenesis 
were described in periodontal disease by Page and Schroeder 
(1976). The first stage, or the initial lesion, occurs 4 
to 7 days following the accumulation of plaque. There is a 
classical vasculitis of the vessels subjacent to the 
junctional epithelium, a dramatic increase in the number of 
neutrophils present in the junctional epithelium in the 
gingival crevice, exudation of fluid from the gingival 
sulcus, the presence of serum proteins in the GCF, 
alteration in structure of the most coronal portion of the 
junctional epithelium, and loss of perivascular collagen. 
If the plaque is left undisturbed, within 4 to 7 days the 
early stage develops. At this stage, there is a large 
portion of collagen lost from the junctional epithelium, 
proliferation of the basal cells of the junctional 
epithelium begin, cytopathic effects on the gingival 
fibroblasts occur. There is a dramatic increase in the 
number of leukocytes in the junctional epithelium and 
gingival sulcus and the accumulation of lymphocytes in the 
connective tissue, which are predominantly T cells 
(cellular immune response). These two lesions characterise 
the acute stage of gingival inflammation. Two to three 
weeks of plaque accumulation are required before the third 
stage, referred to as the established lesion, occurs. 
At this stage, there is a persistence of a large
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number of plasma cells in the infiltrate, however there is 
no appreciable bone loss. This stage is a B cell response. 
There is greater proliferation and apical migration of the 
junctional epithelium, and it's lateral extension becomes 
more pronounced. Early pocket formation may be present. 
This lesion represents chronic gingivitis rather than acute 
gingivitis. The three previous stages define gingivitis. 
The fourth stage, or the advanced lesion, is characterised 
by loss of connective tissue attachment in root surface, 
and apical migration of junctional epithelium. In addition 
there is persistence of the histological features described 
for the established lesion, there is pocket formation that 
is associated with the loss of alveolar bone and a 
predominance of B cells or plasma cells. This lesion is 
equivalent to periodontitis.
Chronic inflammation plays an important role in periodontal 
destruction. It is now established that initiation and 
maintenance of the inflammatory process is due to factors 
produced/released by subgingival microbiota. For a number 
of years, two general mechanisms of pathogenesis have been 
suggested. The first involves invasion by subgingival 
species. It has been shown that bacterial hydrolytic 
enzymes can attack critical components of the intercellular 
matrix of epithelial and connective tissue. Recent studies 
indicate that some micro-organism release a variety of 
soluble factors which have detrimental effects on the host, 
such as Actinobacillus actinomycetemcomitans which produces
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leucotoxin. Apart from direct damage, other microbial 
substances may causes indirect damage to the host tissues. 
They activate endogenous cellular and hormonal inflammatory 
systems which affect the integrity of the periodontium. 
The activated cells include macrophages, lymphocytes, 
fibroblasts, and keratinocytes. Endothelial cells and PMNs 
in turn produce or release mediators such as interleukin-1 
(IL-1) and tumour necrosis factor-a (TNF-a). Schwartz, 
Stinson & Parker (1972) have shown that lipopolysacharides 
(LPS) of Gram negative bacteria interact with and modulate 
the behaviour of leukocytes and exhibit a wide variety of 
toxic and immunostimulating effects on the host. The 
initiation of the inflammatory reaction is due to endotoxin 
and bacterial derived substances which induce cytokine 
release from host cells, resulting in the activation of one 
or more of the following degradative extracellular pathways 
(Birkedal-Hansen et al., 1993).
The plasminogen-dependent pathway which plays an important 
role in the remodelling of the extracellular matrix in cell 
migration, trophoblast and tumour cell invasion and 
metastasis, and embryonic development and growth (Birkedal- 
Hansen et al., 1993).
The PMN serine proteinase pathway assumes PMN leukocytes 
release two serine proteinases, neutrophil elastase and 
cathepsin G, when triggered. These enzymes have been shown
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to have activity against several extracellular matrix 
proteins, however they do not cleave interstitial collagen 
(Birkedal-Hansen et al., 1993).
The phagocytic pathway which supposes that fibroblasts, 
macrophages and epithelial cells, under certain 
circumstances, phagocytase fragments of collagen fibrils 
(Birkedal-Hansen et al., 1993).
The MMP pathway which plays a substantial part in 
extracellular matrix destruction and remodelling in both 
physiological and pathological conditions (Birkedal-Hansen 
et al., 1993) .
The osteoclastic pathway which assumes that osteoclasts 
initiate the resorptive process by dissolution of the layer 
of osteoid using a collagenase dependent proteolytic 
process which leads to the exposure of the underlying 
mineralised bone surface. The enzymatic mechanisms of 
organic matrix removal from bone and teeth is not 
completely understood (Birkedal-Hansen et al., 1993).
Apart from the above pathways, autoantibodies originating 
from antibodies have a role in the elimination of dead 
cells and constituents of damaged tissue which appear 
during the disease process (Anusaksathien & Dolby, 1991). 
They also play a part in autoimmunity to collagen
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components (Hirsch, 1988) and depression of the host immune 
response during the initial stages of exposure to dental 
plaque (Shenker, 1987) which have been suggested to 
contribute to the pathogenesis of periodontal disease.
1.6 Origin, methods of collection and
volume determination of gingival 
crevicular fluid and rationale for 
gingival crevicular fluid sampling
Gingival crevicular fluid is an inflammatory exudate or a 
pre-inflammatory transudate from the gingival 
microcirculation present in the gingival crevice which 
contains several components from different sources.
The mechanisms of formation and composition of gingival 
crevicular fluid (GCF) , and its flow into and from gingival 
sulci, and gingival and periodontal pockets, are not 
understood.
However, it has been suggested that components of the GCF 
may be assumed to originate from 4 main sources; a) 
breakdown of the host epithelial and connective tissues; b) 
products of host cells in the periodontium; c) plasma 
derived molecules; d) products derived from the subgingival 
microbial plaque.
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Loe and Holm-Pedersen (1965) demonstrated that the gingival 
fluid is an inflammatory exudate and that the flow starts 
before structural changes can be ascertained at the 
clinical level and persists some time after clinical 
inflammation has resolved. They also showed that the level 
of GCF increased with increasing gingival inflammation. 
Furthermore, Curtis et al. (1988) suggested that the high
protein values reflect either the method of sample 
collection or the degree of gingival inflammation, rather 
than being an indicator of destructive disease in the 
periodont ium.
Recently, Griffiths et al. (1992) investigated the
association between clinical periodontal indices and both 
the volume and flow rate of GCF in adolescents. These 
investigators concluded that flow rate indicates variations 
in tissue permeability more precisely than clinical 
assessments of inflammation.
Based on the amount of fluid required and the type of 
analysis to be performed, methods of collection of GCF 
differ. Paper strip/paper points, capillary tubes or 
micropipettes and gingival washing are various methods of 
collection of GCF. Most investigators use paper strips or 
small micropipettes to collect GCF. When cell types and 
numbers in the fluid are required, gingival crevicular 
washings are used (Adonogianaki et al. , 1993) . Whereas if
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large volumes of GCF are required, capillary tubes 
(Larivee, Sodek & Ferrier, 1986) or micropipettes 
(Eisenhauer et al., 1983) are employed.
•Gingival crevicular fluid is currently used in diagnostic 
tests, in the hope of: a) detecting the presence of disease 
and identifying patients at risk before biological onset 
occurs; b) evaluating the severity of disease; c) 
predicting the subsequent clinical course and prognosis of 
the disease; d) reducing the time between biological onset 
and usual clinical diagnosis; e) estimating the response to 
treatment before additional therapy is investigated; f) 
assessing the actual response, after completion of 
treatment.
The accurate and reproducible sampling of fluid is
important; a number of studies have demonstrated that the 
choice of collection device (Brill, 1962; Sueda et al., 
1969; Takamori, 1963; Oppenheim, 1970; Egelberg & Attstrom, 
1973), the various materials for sampling (Nakashima et
al., 1994), the length of collection time, the number of
sample repetitions (Binder et al. , 1987 & Persson & Page,
1990) and the calculation of data as absolute measures or 
as flow rates (Lamster et al., 1985), contribute in a large 
measure to overall variability. As well as these 
variables, expected fluctuations based on the operator-
sensitive use of collection devices exist (e.g., the depth
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of insertion of the filter-paper strip or capillary tube). 
The potential depletion of the sample by a prolonged 
collection time (Persson & Page, 1990), the potential 
contamination by serum components (Lamester et al. , 1985),
the loss of the sample from the collection device 
(Rossomando, Kennedy & Hadjimichael, 1990), and the
differences between sites (Smith & Geegan, 1991) are also 
factors which affect variability.
Reports have varied relating to a positive correlation 
between the quantity of GCF and clinical signs of gingival 
inflammation. The rate of renewal of epithelial
structures, and the passage of leukocytes through the 
junctional epithelium modulate the concentration of various 
enzymes in the gingival crevice. This concentration will 
also depend upon the endogenous production of enzymes, 
either in the periodontal tissues or transported locally by 
blood. Furthermore, the presence of bacteria significantly 
modifies the enzymatic content of the crevice (Cimasoni, 
Ishikawa & Jaccard, 1977) .
1.7 Matrix metalloproteinases (MMP)
The matrix matalloproteinases (MMPs) are a group of zinc 
enzymes which are responsible for remodelling and 
degradation of the extracellular matrix components.
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1.7.1. Sources, the Matrixin family, the structure
of matrixin and the molecular biology of the 
matrix metalloproteinases
The MMPs comprise at least nine members, each of which is 
the product of a different gene (Woessner, 1991; Birkedal 
et al. , 1993; Murphy & Docherty, 1992) (Table 1.1).
Metalloproteinases are classified, based on substrate 
characteristics into three subclasses: collagenases (MMP-1) 
and (MMP-8), gelatinases (MMP-2 and MMP-9), and 
stromelysins (MMP-3, MMP-10 and MMP-11).
Collagenases are produced from different sources such as 
polymorphonuclear neutrophils and resident fibroblasts and 
also from other cells e.g. keratinocytes, endothelial 
cells, monocytes/macrophages, osteoblasts, and
chondrocytes. Two types of mammalian collagenases have 
been identified in the GCF, the fibroblast type (matrix 
metalloproteinase l/MMP-1) and neutrophil collagenase (MMP- 
8) . These enzymes are different gene products, they 
principally catalyse the same reaction, but differ in their 
antigenic properties (Hasty, et al., 1984), and molecular 
size (Sorsa et al. , 1987, 1988). The enzyme of fibroblast 
origin has a smaller molecular mass than the one of PMN 
origin. Metalloproteinases which are produced by
fibroblasts are synthesised by initial transcription of the 
corresponding genes which lasts for a period of 6 to 12
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Table 1.1 Matrixin
Enzyme Abbre. MMP # Mr Human@ Substrates
Fibroblast
type
collagenase
FIB-CL MMP-1 57 Gllq22 Collagen I, II, 
III, (lll»i), 
VII, VIII, X; 
Gelatin; PG 
core protein
PMN type 
collagenase
PMN-CL MMP-8 75 ♦ same as FIB-CL 
(I/ III)
Stromelysin-1 SL-1 MMP-3 60 ♦llq22 PG core 
protein; 
fibronectin; 
laminin; 
collagen IV, V, 
IX, X; elastin; 
proCL
Stromelysin-2 SL-2 MMP-10 60 ♦llq22 Same as SL-1
Stromelysin-3 SL-3 MMP-11 * ♦22qll *
Mr 72k 
gelatinase/ 
type IV
Mr 72k 
GL
MMP-2 72 G16q21 Gelatin; 
collagen IV, V, 
VII, X, XI; 
fibronectin; PG 
core protein
Mr 92k 
gelatinase/ty 
pe IV 
collagenase/
Mr 92k 
GL
MMP-9 92 G16q Gelatin; 
collagen IV, V, 
elastin; PG 
core protein
gelatinase B
Macrophage MME MMP-12 53 ♦ Elastin
metallo-
elastase
Matrilysin PUMP-1 MMP-7 28 G Fibronectin;
laminin, 
collagen IV, 
gelatin' ProCL, 
PG core protein
♦ DNA sequence, G genomic sequence, llq chromosome location
Mr molecular weight (kD)
* not determined
@ Known sequences and gene structures in human 
Abbre. Abbreviation
Modified from Birkedal-Hansen et al. (1993) and Woessner, (1994).
hours before the enzyme can be detected in the 
extracellular environment. Once the enzyme can be detected 
production and secretion can be sustained for several days. 
The PMN-collagenases are synthesised during the development 
of PMNs and stored in specific granules and are rapidly 
released when the cell is triggered.
The stromelysins include SL-1, SL-2, and SL-3 which cleave 
a wide rang of extracellular matrix proteins such as 
proteoglycan core protein, fibronectin, laminin, and type 
IV and V collagen. They have identical substrate
specificities. The enzymes do not appear to be expressed 
by PMN leukocytes and keratinocytes in the human, but SL-1 
is expressed by stromal cells either constitutively or 
after induction by growth factors/cytokines such as IL-1 
and TNF-a.
Gelatinase is produced by keratinocytes, PMN leukocytes, 
and monocytes/macrophages, and occasionally by fibroblasts. 
GL has been identified in fibroblasts, keratinocytes, 
endothelial cells, monocytes/macrophages, osteoblasts, and 
chondrocytes. Gelatinases cleave gelatin and also types 
IV, V, VII, and X collagens and elastin. They are 
expressed by PMN leukocytes, Keratinocytes, monocytes and 
fibroblasts and also are present in a circulating form in 
the plasma (reviewed by Birkedal-Hansen et al., 1993).
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The matrixins have several structural features in common 
that include a) a propeptide domain that contains the 
''cysteine switch77; b) a catalytic zinc-binding domain; 
and c) a hemopexin-like domain (Birkedal-Hansen et al. , 
1993; Docherty & Murphy, 1990). The propeptide domain (N- 
terminal) that contains the 'cysteine switch7, is not 
required for catalysis but does play a role during the cell 
membrane-mediated activation of the proenzyme (Murphy et 
al., 1992). Matrix metalloproteinases are secreted as a
proenzyme and then activated by a proteolytic process which 
removes an amino acid propeptide from the N-terminus. The 
catalytic domain (C-terminal domain) includes the zinc- 
binding domain that acts as a catalytic base and contains 
the active site of the enzyme. The C-terminal domain 
modulates the binding of TIMPs to the active centres of the 
matrixins and maintains latency of the matrixins until a 
signal for activation is given (Woessner, 1994). The 
function of the hemopexin/vitronectin domain is not 
completely clear. TIMPs bind to the hemopexin domain of 
the enzyme, because it is close enough to the active centre 
to interfere with the autoactivation step and with the 
activated form of the enzyme (Figure 1.2).
Woessner (1994) outlined the four criteria required for 
membership of the family matrixins of MMPs: a) the enzyme
should display proteolytic activity; b) the enzyme should 
function outside the cell; c) its cDNA should code for a
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MMP-1
PMN-CMMP-3
MMP-3
Figure 1.1 Domain structure of matrix metalloproteinases
Modified from Birkedal-Hansen et al. (1993).
protein sequence for the cysteine switch mechanism; d) its 
cDNA should code for a protein sequence for the binding of 
catalytic zinc.
1.7.2 Activation of matrix metalloproteinases
The MMPs are synthesised in a proenzyme form, and 
activation occurs after leaving the cell. In vivo, it is 
likely that the procollagenases are activated by 
proteolytic cleavage catalysed by other proteinases such as 
plasmin. Plasminogen may be expected to enter from the 
blood vessels and the mesenchymal cells can produce 
plasminogen activators; the activity of stromelysin is 
probably required for complete activation (Figure 1.2) 
(Harris & Vater, 1982; Goldberg et al. , 1990). Upon
activation, the propeptide domain is cleaved away in 
several steps. Metalloproteinases can be activated by so 
many different agents in vitro, such as organomercurials, 
trypsin and plasmin. The activation by plasmin is still 
under question; there may be other activating proteinases. 
Furthermore, it has been shown that P. gingival is can 
activate latent FIB-CL and to a lesser extent PMN-CL (Sorsa 
et al., 1992).
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Plasminogen
Activator
Inhibitors
TIMPs
TIMPsCollasenase
Plasmin
Stromelvsin
Pro-Strom elvs in
Pro-Collasenase
Plasminogen
Plasminogen Activator
Figure 1.2 Pathways for activation and inhibition of 
collagenase and stromelysin 
Modified from Krane, 1994.
1.7.3 Regulation of matrix metalloproteinases
The matrixins are regulated at many points; a) Regulation 
occurs at the level of gene expression; b) Regulation at 
the level of secretion is recently been shown to be 
important in epithelial cells; c) Regulation at the level 
of zymogen activation has been performed by inhibitors of 
the extracellular matrix. Collagenase, stromelysin-1, and 
TIMP's regulation has co-ordinated by a variety of stimuli 
(Brinckerhoff et al., 1979; Werb & Reynolds, 1974; Wrana et 
al. , 1986). Although, early workers believed that 'co­
ordinated regulation, ' was a general feature of MMP and 
TIMP regulation, it is now clear that MMP and TIMP 
expression can be independently regulated (Overall, 1994) .
Briefly, extracellular regulation of MMP activity can be 
achieved in four different ways namely: a) Transcriptional 
regulation of MMP genes; b) Precursor activation; c) 
differences in substrate specificity; and d) MMP 
inhibitors.
Transcriptional regulation
Cytokinases, morphogens and growth factors involved in 
cellular differentiation and tissue morphogenesis such as 
transforming growth factor-ftl (TGF-ftl) (Overall, 1994), 
have been shown to regulate the expression of inhibitors of
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matrix metalloproteinases (TIMPs). TGF-fl decreased the 
production of collagenase and amplified the induction of 
TIMP-1, mediated by epidermal growth factor and fibroblast 
growth factor (Edwards et al., 1987) . In contrast, other 
cytokines, such as interleukin-1 (IL-1) (Murphy et al., 
1985), epidermal growth factor and fibroblast growth 
factor, and tumour necrosis factor-a (TNF-a) (Meikel et 
al., 1989) increase collagenase, stromelysin-1, and TIMP-1
expression. Whereas concanavalin A induces MMP production 
and decreases TIMP-1 and TIMP-2 synthesis (Overall et al.,
1991) .
Activation of precursor
The MMPs are synthesised in an inactive form that is later 
activated. It is likely that the procollagenases are 
activated by proteolytic cleavage catalysed by other 
proteinases such as plasmin. The activity of stromelysin 
is probably required for complete activation (Goldberg et 
al., 1990; Woessner, 1991). Therefore, the process of 
activation of the precursors in the extracellular matrix, 
is another stage in the regulation of MMP.
Substrate Specificity
The different types of substrate have been shown to be one 
of the factors involved in regulation of MMP activity.
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Accordingly, regulation of cell function is affected by 
changes in the extracellular matrix composition. At the 
tissue level, this affects tissue morphology and function, 
while at the cellular level, changes in the composition of 
the extracellular matrix influence cell adhesion, 
migration, differentiation, and activity. The enzymes have 
some overlapping effects on the substrate, however there 
are some differences with respect to their function. 
Interstitial collagen fibrils are dissolved by FIB-CL and 
PMN-type collagenases, however this ability is not shared 
by other members of the family.
MMP Inhibitors
Regulation at the sites of zymogen activation can be 
performed by inhibitors of the extracellular matrix. These 
are chiefly a2-macroglobulin and members of the TIMP 
family. a2-macroglobulin plays an important role in the 
regulation of MMP activity by rapid capture of the 
proteinase. Tissue inhibitors of metalloproteinases
(TIMPs) bind to the active forms of the enzyme forming 1:1 
complexes and block their activity.
Overall (1994) demonstrated that MMPs can be independently 
regulated and suggested that MMP and TIMP levels in tissue 
extracts or inflammatory exudates do not necessarily
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reflect the response of individual cells, but rather of the 
cell population as a whole.
1.7.4 Tissue inhibitors of matrix
metalloproteinase (TIMP)
TIMPs are glycoproteins and form firmly bound complexes 
with metalloproteinases resulting in the blocking of their 
activity (Cawston et al. , 1983). Three forms of TIMP have
been identified, TIMP-1 and TIMP-2 are secreted by many 
cells (Stetler-stevenson, Krutzsch & Liotta, 1989; Welgus & 
Stricklin, 1983) and are found in serum, amniotic fluid 
(Welgus & Stricklin, 1983; Murphy, Cawston & Reynolds, 
1981), and saliva (Drouin et al. , 1988). Their regulation 
at the gene level appears to be very different, TIMP-1 
expression is very tightly controlled by many cytokines and 
growth factors whereas little has yet been found that 
regulates TIMP-2. The two TIMP genes are differently 
regulated. TIMP-3 is less well understood. All three 
types of TIMP consist of two structurally distinct domains; 
the N-domain which reacts with the active centres of most 
of the matrixins, and the C-terminal domain, a functional 
MMP inhibitor, which interacts with the enzyme's catalytic 
domain. All TIMPs form high-affinity, noncovalent, and 
reversible complexes with the active forms of MMPs. TIMPs 
mechanism of inhibition is unknown. TIMPs bind to MMPs,
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this binding is in the hemopexin domain, but it is close 
enough to the active centre to interfere with the 
autoactivation step and with the activated form of the 
enzymes. TIMP is also known to inhibit leukocyte 
collagenase less effectively than the fibroblast type 
interstitial collagenases (Bunning et al., 1984).
Activated forms of FIB-CL , as well as SL-1 and SL-2, form 
complexes with both TIMP-1 and TIMP-2 whereas the full- 
length latent proenzymes do not (Bodden et al., 1994).
Thus, remodelling of connective tissue matrices can be 
controlled through the precise modulation of MMP and TIMP 
expression.
1.7.5 Other inhibitors of matrixin
The extracellular protease activity is modulated by broad 
spectrum inhibitors, mainly al-antitrypsin (al-AT) and 
a2-macroglobulin (a2-M) which accounts for more than 95% 
of metalloproteinase inhibition in plasma. Both al- 
antitrypsin and a2-macroglobulin are detected in gingival 
crevicular fluid during periodontal disease (Adonogianaki 
et al., 1992; Gustafsson et al., 1992). The evidence
suggests that a2-macroglobulin plays an important role in 
the regulation of MMP activity. The rapid capture rates, 
particularly with collagenase, render the reaction all but 
instantaneous. Cawston and Mercer (1986) showed that in a
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mixture of TIMP and a2-M, collagenase binds preferentially 
to a2-M. It is also of note that the concentration of a2-M 
in the interstitial fluid is quite considerable. ot2-M 
concentrations in gingival crevicular fluids (GCFs) from 
variously inflamed sites have yielded values from 0.2 to 
2.4 mg/ml. These studies suggest that a2-M concentrations 
in interstitial fluids are as much as 100 to 1000 fold 
greater than those of TIMPs.
The protease inhibitor complex is rapidly eliminated by the 
reticuloendothelial system, from the circulation by the 
liver and from local areas of inflammation by phagocytes 
(Travis & Salvesen, 1983).
1.7.6 The role of matrix metalloproteinases in the
pathogeneses of the periodontal disease
Numerous studies have shown MMPs as key players in 
periodontal tissue destruction (Sorsa et al., 1988; Kinane, 
1992; Ingman et al., 1994b, 1995) . The detection of
pathologically elevated levels of MMPs in extracts of 
inflamed gingival tissues, GCF, plaque, and 
salivary/mouthrinse samples has been recorded. It has been 
found that collagenase activity (Villela et al., 1987), and 
also the amount of these enzymes in GCF are increased with 
increasing severity of periodontal disease (Haerian et al.,
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1995a). Kryshtalskyj, Sodek & Ferrier (1986), Kryshtalskyj 
& Sodek (1987) and Larviee et al., (1986) demonstrated that
the activity of these proteinases was positively correlated 
with severity of periodontal inflammation and pocket depth 
of diseased sites. However, Uitto, Suomalainen and Sorsa, 
(1990) demonstrated that in saliva obtained from 
periodontitis patients, collagenase was recovered in an 
active rather than in a latent form whereas in healthy 
individuals collagenase was partially latent. The origin 
of these enzyme in saliva was PMN. Furthermore, it has 
been shown that periodontal therapy decreases collagenase 
activity (Larivee et al., 1986; Hakkarainen, Uitto &
Ainamo, 1988; Yanagimura, Koike & Hara, 1989) and also 
decreases the amount of collagenase and stromelysin (SL) in 
the GCF (Haerian et al., 1995b) . Sorsa et al. (1995)
reported that in dental plaque from adult periodontitis, 
human and bacterial collagenase activity can be 
distinguished in both supra and sub gingival dental plaque.
Data from previous research indicates that a combination of 
debridement and antibiotic administration may reduce the 
incidence of active lesions in patients who appear to be 
refractory to conventional treatment (Loesche et al., 1984; 
Gusberti, Syed & Lang, 1988). However, the cellular sources 
of MMPs present in inflamed human gingiva, GCF, dental 
plaque, and saliva and also the type of collagenases found 
in different categories of periodontitis are important to
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the understanding of the pathogenic mechanisms of 
periodontal disease. Therapeutic strategies may be
directed toward reducing pathologically excessive MMP 
levels in different forms of periodontal disease (Golub, 
Suomalainen & Sorsa, 1992). Recently, Sorsa et al. (1994) 
investigated the presence of different molecular forms of 
tissue inhibitors of matrix metalloproteinases (TIMP1 and 
TIMP2) in dental plaque, GCF and saliva, by Western 
blotting, using specific antisera. These workers
discovered that latent pro MMP-8 and active MMP-8 were 
found in the saliva and GCF of individuals with periodontal 
disease. Whereas they were not found in GCF of healthy 
subjects. MMP-8 was found in sites with high levels of 
inflammation in localised juvenile periodontitis (LJP) 
subjects. TIMP-1 and TIMP-2 were found in the dental 
plaque and saliva of patients with adult periodontitis and 
LJP, whereas these enzymes were not detected in the GCF of 
these groups of patients.
Accordingly, based on the above findings and those of other 
studies, the authors concluded that the following factors 
have an effect on the results: a) the form of periodontitis 
which the subject has; b) the type and origin of the 
proteins being analysed; c) the laboratory techniques 
employed; and d) the way in which the results are 
expressed.
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1.8 Treatment of periodontal disease
The purposes of treatment in periodontal disease are as 
follows: a) to control or eliminate microbial plaque; b) to 
arrest the progression of further destruction; c) to 
restore function and aesthetics; d) to prevent the 
recurrence of the disease. These aims are accomplished by; 
a) motivating and teaching the patient to perform oral 
hygiene effectively; b) scaling and root planing; c) the 
removal of additional retention factors for plaque such as, 
overhanging margins or restorations (Lindhe, 1989) .
Mechanical instrumentation produces not only a reduction in 
the microbial mass within subgingival pockets but also 
causes an alteration in the subgingival ecosystem and hence 
reduces the proportion of periodontopathic micro-organisms 
returning the flora to one more compatible with health 
(Magnusson et al., 1984).
The effect of mechanical debridement compared with the use 
of an antibiotic is superior in terms of reducing the total 
amount of plaque micro-organisms, nevertheless antibiotic 
therapy can be effective in the direct elimination of 
specific pathogens.
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1.8.1 Antibiotics in the management of periodontal
disease
Antibiotics are thought to reduce the pathogenicity of the 
microflora, and hence affect the clinical signs of 
periodontal disease (Reviewed by Symour & Heasman, 1995). 
Antibiotics have often been used against acute lesions 
elsewhere in the body, and it has been difficult to justify 
a similar efficacy in the treatment of periodontal disease. 
At present, there seems to be no overall agreement as to 
the use of antibiotics in the treatment of periodontitis, 
although many periodontists appear to accept their 
prescription for controlling some forms of rapidly 
progressive and refractory disease (Slots & Rams, 1990; 
Fiehn, 1990; Van Winkelhoff & de Graaff, 1991; McCulloch et 
al., 1990). The following section will discuss the 
antibiotics which are used in periodontal disease.
1.8.2 Rational for the use of antibiotics in
periodontal disease
In recent years, it has been found that micro-organisms are 
directly involved both in the initiation and the 
progression of destructive periodontal disease. The 
evidence to support this contention has been extensively 
documented in a number of reviews (Genco, Evans & Ellison,
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1969; Socransky, 1977; Haffajee & Socransky, 1994).
Evidence suggests that specific micro-organisms have been 
implicated as playing an important role in the breakdown of 
periodontal tissue (Armitage et al., 1982; Moore, 1987;
Slots & Listgarten, 1988). The ''Specific plaque
hypothesis'' was put forward by Loesche in 1976. He 
suggested that only a small number of species of micro­
organism within the bacterial mass are the main 
aetiological factor in gingivitis and periodontitis. 
Furthermore, Socransky (1977) demonstrated that specific 
groups of bacteria are associated with specific clinical
forms of periodontal disease. With regard to this
hypothesis, interest has grown regarding the use of 
antimicrobial therapy for periodontal disease as a means of 
reducing the level of pathogenic bacteria in the 
subgingival area.
There are two approaches which can be taken to make the 
subgingival area less pathogenic. The first would be to 
reduce the total microbial mass. The use of non-specific 
antiseptic agents against the plaque microflora and 
mechanical debridement of the root surface would serve this 
purpose. The other approach would be to reduce the level 
of pathogenic micro-organisms in the plaque. To this end, 
antibiotics would be considered to be the most effective 
choice.
29
1.8.3 Common antibiotics used in the treatment of
periodontal disease
Microbiological parameters clearly revealed that 
chemotherapy directed towards the anaerobic micro-organisms 
in the subgingival plaque substantially reduced it's 
pathologic potential (Slots et al. , 1979; Lundstorm,
Johansson & Hamp, 1984; Loesche et al. , 1984). Four
principle groups of antibiotics have been extensively 
tested in the treatment of periodontal disease; these are 
the penicillins, clindamycin, metronidazole and the 
tetracyclines.
The penicillins and clindamycin have found only limited 
application in the control of periodontal inflammation 
(Slots & Rams, 1990) .
Penicillins (penicillin v, ampicillin, amoxycillin,...) are 
the antibiotics of choice for premedication as well as for 
nonperiodontal oral infection. Amoxycillin and ampicillin 
have proved useful in the treatment of acute necrotising 
ulcerative gingivitis and severe periodontal disease (Van 
Winkelhoff et al., 1989). Augmentin (amoxycillin and 
clavulanic acid) has shown promise in the treatment of 
refractory periodontitis (Kornman et al., 1989). The major 
disadvantages of penicillins are the high incidence of
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immediate hypersensivity type allergic reactions and the 
development of penicillin resistant micro-organisms.
Clindamycin has been shown to be useful for the treatment 
of refractory periodontitis (Gordon et al. , 1990; Walker &
Gordon, 1990). An important complication occasionally seen 
with clindamycin is the development of pseudomembranous 
colitis.
Metronidazole and tetracyclines have been extensively used 
in the treatment of periodontal disease.
Metronidazole
Metronidazole is a nitromidazole with a narrow range of 
activity against anaerobes, such as Bacteroides species and 
spirochetes, which are generally believed to be the major 
pathogens associated with periodontitis. Metronidazole is 
bactericidal at low concentrations (Sutter, Jones & 
Ghoneim, 1983; Wade & Addy 1987; Walker et al., 1985). It 
was discovered in France during the 1950s (Scully, 1988) . 
In the 1962, it was confirmed to be effective in the 
treatment of Trichomonas vaginalis infection, and 
ulcerative gingivitis (Shinn, 1962). Subsequently, it was 
reported that metronidazole killed spirochetes (Davies, 
MacFadzen & Squires, 1964). In the early 1970s,
investigators observed that it was bactericidal for
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obligate anaerobes (Tally, Sutter & Finegold, 1972) . Since 
periodontal disease was often associated with anaerobic 
bacteria, metronidazole was assessed alone and in 
conjunction with conventional therapy to determine if its 
use could improve periodontal status (Jenkins et al., 1989; 
Gusberti, Syed & Lang, 1988; Soder et al., 1990; Loesche et 
al., 1992) .
The principal members of this group are metronidazole, 
tinidazole and ornidazole, and they have been prescribed 
alone, or in combination with other antibiotics, for 
example, amoxicillin (Van Winkelhoff et al. , 1989; Van
Winkelhoff, Tijhof & de Graaff, 1992) or augmentin (Kornman 
et al., 1989) in the treatment of severe infections. 
Various combinations of metronidazole have been found to 
have an anti-plaque potential. There has been little 
evidence of tinidazoles efficacy in the treatment of 
chronic periodontitis. Metronidazole is well absorbed 
after oral administration and penetrates into body tissues, 
cerebrospinal fluid, saliva and can be detected in the 
gingival crevicular fluid (GCF) (Britt & Pohlod, 1986) . It 
is metabolised in the liver, the unchanged drug and the 
metabolites are excreted in the urine (Plaisance, 
Quintilian & Nightingale, 1988). Concurrent food ingestion 
does not inhibit bioavailability; however absorption may be 
slowed. Britt and Pohlod (1986) reported that the 
concentration found in the GCF is only half that found in
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the serum. Metronidazole gains access to aerobic and 
anaerobic bacterial cells by diffusion.
Metronidazole has been used orally in tablet form and for 
topical application. Various dosages and durations of 
metronidazole therapy have been used in the treatment of 
periodontal patients. The most commonly prescribed drug 
regimen was 200 to 250 mg three times a day (tid) for 7 
days (Jenkins et al., 1989; Loesche et al., 1991, 1992). 
Local application of metronidazole in devices such as 
pulsed-jet irrigators, acrylic strips, dialysis tubing, 
subgingival displacement pressure packs and dental paste 
was found effective as an adjunct to conventional treatment 
(Aziz-Gandour & Newman, 1986; Khoo & Newman 1983; Newman et 
al. , 1984; Addy, Langeroudi & Hassan, 1985; Addy et al., 
1988; Yeung, Newman & Addy, 1983; Klinge et al., 1992).
Numerous side effects have been recorded which are not 
often serious. These are gastrointestinal discomfort,
diarrhoea, nausea, loss of appetite, a bitter and metallic 
test, urticaria, and discoloured urine. Dizziness and 
headaches have also been reported. Occasionally skin 
rashes have occurred. Patients who are prescribed
metronidazole, should be instructed not to take alcohol as
the drug may inhibit alcohol metabolism. Patients
undergoing anticoagulant therapy can be affected by 
metronidazole because it inhibits warfarin metabolism,
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thereby prolonging prothrombin time. Similarly,
individuals taking lithium should also avoid metronidazole, 
because even short-term usage of metronidazole can cause 
elevated serum lithium levels. Administration of
metronidazole in pregnancy should be avoided especially in 
the first trimester.
Tetracyclines
The tetracyclines are broad-spectrum bacteriostatic 
antibiotic agents which are effective against a number of 
oral Gram-negative and Gram-positive cocci and bacilli. 
Tetracyclines are also effective against many anaerobic and 
facultative bacteria, which is especially relevant from a 
periodontal standpoint. They are also active against most 
spirochetes. Chlortetracycline was the first tetracycline 
isolated from the fermentation products of streptomycin 
aureofaciencs which were initially obtained from soil 
micro-organisms. They were introduced into clinical 
practice in 1948 (Duggar, 1948). Tetracyclines have also 
been used in dentistry, particularly as adjuncts to 
periodontal therapy (Reviewed by Seymour & Heasman, 1995) . 
There are several different kinds of tetracyclines 
available on the market. Tetracycline hydrochloride, 
doxycycline and minocycline which are all semisynthetic 
tetracyclines, are used extensively in the treatment of 
periodontal disease.
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The tetracyclines, especially minocycline and doxycycline, 
are lipophilic and are thus highly diffusible, resulting in 
their antibacterial action, and also reflecting their 
ability to penetrate developing dental structures and bone 
and also enter the cerebrospinal fluid, and crevicular 
fluid. The tetracyclines, minocycline, and doxycycline are 
detectable in the GCF after oral administration and their 
concentrations can reach levels of 10 times and 5 times 
respectively, those in serum. This is of particular 
importance when the drugs are used for the treatment of 
periodontal disease. Minocycline has a longer serum half- 
life and a lower urinary excretion rate than most other 
tetracyclines which permits the use of smaller and less 
frequent doses (Genco, 1981).
Tetracyclines are absorbed from the gastrointestinal tract. 
Absorption is fairly rapid, but significant amounts are 
retained in the bowel. The absorption of tetracycline is 
reduced when the drugs are taken with milk products or with 
substances containing calcium, magnesium, iron, or 
aluminium. Therefore it is advisable to refrain from these 
products for at least an hour and a half prior to or 
following administration of the medication by the oral 
route. However, food does not interfere with the 
absorption of doxycycline or minocycline. Excretion of the 
tetracyclines occurs in both the urine and the faeces, but 
mainly via the kidneys. There is some reabsorption of the
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drug which prolongs their duration of action. Doxycycline 
and minocycline are excreted predominantly in the faeces. 
The tetracyclines are bacteriostatic antimicrobials that 
exert their antibacterial activity by inhibiting microbial 
protein synthesis (Chopra & Howe, 1978).
The tetracyclines have been administered both orally and 
topically in periodontal treatment (Goodson, Haffajee & 
Socransky, 1979; Goodson et al., 1983; Lindhe et al., 
1979). The most commonly prescribed regimen was 200 to 250 
mg at six-hourly intervals for two weeks (Slots et al., 
1979; Rams & Keyes, 1983) for tetracycline hydrochloride. 
The adult dosage for doxycycline is a loading dose of 200 
mg, followed by 100 mg/day for 7 days; for minocycline is 
100 mg twice a day for a week. Tetracyclines have been 
applied in different delivery devices such as cellulose 
acetate fibres (Lindhe et al. , 1979), hollow fibres
(Goodson, Haffajee & Socransky, 1979; Lindhe et al., 
1979), ethyl cellulose fibres (Friedman & Golomb, 1982), 
acrylic strips (Addy et al., 1988; Addy, Langerondi & 
Hassan 1985), collagen preparations (Minabe et al., 1989, 
1991), white petrolatum (Eckles et al., 1990), inserts of 
polymethacrylic acid with hydroxypropylcellulose (Higashi 
et al., 1990), hydroxypropylcellulose films (Noguchi et 
al., 1984), powder (Okuda et al., 1992), ointment (Rosania 
& Kornman, 1981), solution (MacAlpine et al., 1985;
Puchalsky et al., 1988), gel (Van Steenberghe et al. ,
36
1993), ethylene vinyl acetate copolymer (EVA) fibres 
(Goodson et al., 1983).
The side effects of tetracyclines are hypersensitivity 
reactions, gastrointestinal disturbances, nausea, vomiting 
or diarrhoea, and pseudomembranous colitis. Candida 
albicans has also been reported in patients who have 
received a long course of treatment with tetracycline. 
Large doses of tetracyclines given parenterally can damage 
the liver; pregnant woman appear to be particularly 
susceptible. Immediately after absorption, tetracyclines 
are built into calcifying tissue and become a permanent, 
discolouring feature of the teeth, if administered to 
children under 12 years of age. The use of tetracyclines 
should be avoided during the period of crown formation of 
the teeth.
1.8.4 Local versus systemic delivery of
antibiotics in periodontitis therapy
The purpose of using an antimicrobial is to achieve a 
sufficient concentration of the drug in the periodontal 
environment to kill or arrest the growth of pathogenic 
micro-organisms. With systemic antibiotic therapy the 
concentration at the site of infection is dependent on the 
level achieved in the serum. The concentration at the site
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of infection is relatively low, because the administered 
dose is distributed throughout the blood stream. Several 
studies have shown that the concentration of some 
antibiotics in the GCF is equal to or 10 times more than 
that of the serum. However, local antibiotic
administration can accomplish 100 fold concentrations at 
subgingival sites than can be achieved by systemic therapy 
(Goodson et al. , 1985a) . One of the principal aims of
current periodontal antibiotic research is to reduce the 
need for systemic prescription with the disadvantage of 
potential adverse side-effects. This becomes even more 
relevant when considering evidence that crevicular fluid 
levels achieved using local antibiotic therapy were 
adequate to inhibit all cultivable organisms in a given 
subgingival plaque (Wilson, O'Connor & Newman, 1990, 1991). 
Furthermore, local therapy enables the utilisation of 
antimicrobial agents which do not lend themselves to 
systemic administration. Subgingival irrigation suppresses 
the subgingival microbiota for at least a short period of 
time.
1.8.5 Clinical efficacy of antibiotics in
periodontal disease
Several studies compared the ability of antibiotic therapy 
alone to favourably alter clinical and microbiologic
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parameters, with root planing. These investigations 
indicated that drug therapy alone was inferior to
mechanical instrumentation (Lindhe, Liljenberg & Adielson, 
1983; Walsh et al. , 1986; Lekovic et al. , 1983). With
regard to the above conclusion, several further studies 
suggested the use of antibiotics as an adjunct to 
conventional methods in the treatment of periodontal 
lesions (Loesche et al. , 1981, 1984; Lindhe et al., 1982;
Lundstrom, Johansson & Hamp, 1984; Soder et al., 1990). 
The results from clinical trials using antibiotic therapy 
alone and as an adjunct to conventional therapy are
controversial. Jenkins et al. (1988) concluded that
antibiotic therapy could not be justified in patients with 
poor plaque control.
A 6 month multicenter clinical trial of 206 patients was 
conducted comparing metronidazole gel application to 
scaling using a split-mouth design. The results of this 
study suggested that the use of the gel alone without any 
mechanical root-instrumentation reduced pocket depth by 1.3 
mm, however, subgingival root planing gave a statistically 
better reduction (Ainamo et al., 1992). The effect of a 1% 
metronidazole gel was evaluated in 10 patients with 
periodontitis during the maintenance phase as an adjunct to 
scaling and root planing (Needleman & Watts, 1989). There 
was no significant difference in probing depth or
attachment level between teeth treated with 1 %
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metronidazole gel versus teeth treated with a placebo gel 
at 1 and at 3 months post treatment. The results of a 3 
month study of 28 patients which compared the metronidazole 
gel application plus scaling to scaling alone using a 
split-mouth design, failed to show a significant pocket 
depth reduction, or attachment gain between test and 
control groups (Hitzig et al., 1994).
A 12 month study was carried out in 122 patients, comparing 
tetracycline fibres alone to scaling and root planing plus 
tetracycline fibres. This method of slow release of 
tetracycline into the periodontal pocket was shown to be 
effective (Goodson, Haffajee & Socransky, 1979). Analysis 
of data from 107 subjects also indicated that tetracycline 
fibre therapy significantly decreased pocket depth, 
increased attachment level, and decreased bleeding on
probing in two months (Goodson et al., 1991). In a 6 month
study comparing scaling and root planing and tetracycline 
fibres used together with scaling alone, a 40% improvement 
in pocket depth and attachment level was found in the 
former group. The fibres used in conjunction with scaling 
and root planing produced a statistically significant 
improvement in pocket depth reduction, attachment level
gain and bleeding on probing reduction at 6 months after
therapy (Kornman et al., 1993)
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Van Steenberghe et al. (1993) reported a study comparing 
the effect of minocycline gel plus scaling and root planing 
to a placebo gel plus scaling and root planing, in 103 
patients, at one and three months from baseline. Patients 
were randomly assigned to 2 groups in a parallel design. 
There was a statistically significant difference between 
minocycline gel and the placebo gel, in terms of pocket 
depth reduction, at 3 months after treatment (p<0.002). 
There was no significant different between minocycline gel 
and the placebo gel in gain in probing attachment level and 
reduction of bleeding index. There was a significant 
reduction in Actinobacillus actinomycetemcomitans (Aa) , 
Porphyromonas gingivalis (Pg), and Prevotella intermedia 
(Pi) for minocycline treated teeth at 3 months after 
treatment.
Murayama et al. (1989) have demonstrated that following the
treatment of sixteen subjects with scaling and the 
application of 2% minocycline gel there was a decrease in 
plaque accumulation, gingival inflammation, pocket depth, 
bleeding on probing and also a shift of the microflora to 
one associated with healthy gingivae for at least 11 weeks. 
Locally applied minocycline can also prevent bone loss 
(Toth et al., 1986).
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1.8.6 Additional effects of antibiotics
The tetracyclines are now known to have non-antimicrobial 
properties that may also magnify their therapeutic effect. 
These properties are: a) their abilities to bind to the
tooth surface and then be slowly released in an active form 
over a prolonged period of time (Baker et al. , 1983), which 
could prolong their therapeutic effectiveness after the 
patient has stopped taking the drug; b) their anti­
inflammatory action which might be related to the ability 
of tetracyclines to suppress PMN migration, degranulation 
and oxygen radical synthesis, thereby reducing PMN-related 
tissue damage, while simultaneously inhibiting disease 
associated species (Martin et al., 1974; Gabler & Creamer
1991); c) their ability to promote the attachment of 
fibroblasts and connective tissue to root surfaces 
(Somerman et al. , 1988; Rompen et al. , 1993); d) their
ability to inhibit bone resorption (Golub et al., 1984; 
1991; Gomes, Golub & Ramamurthy, 1984); e) their unique 
ability among antibiotics to directly inhibit 
collagenolytic enzymes; f) their ability to recognise the 
cellular source of collagenase in the inflammatory exudate 
from human periodontal pockets, and thereby inhibit its 
activity is, an additional therapeutic role in periodontal 
disease, and is able to used as a diagnostic probe 
(Suomalainen et al., 1992).
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Teng et a l . (1992) showed that metronidazole treatment can
cause the reduction of both active and latent forms of 
gelatinase. They reported that treatment of patients with 
recurrent loss of periodontal attachment, with 
metronidazole (250 mg, tid, for 7 days) significantly 
reduced the level of active and latent gelatinase by 4- to 
6 fold (p<0.002). They concluded that the reduction of 
gelatinase activity is best explained by the antimicrobial 
effect of metronidazole which appears to blunt the 
destructive part of the host immune and inflammatory 
response.
1.8.6.1 Anti-inflammatory effects of tetracyclines
Potential anti-inflammatory properties of tetracyclines 
(Gabler & Creamer, 1991) appear effective in the treatment 
of specific skin disorders which do not have a bacterial 
aetiology. The efficacy of the tetracyclines in the 
treatment of these diseases may be related to their general 
anti-proteolytic properties or to some anti-inflammatory 
properties. Several non-antimicrobial mechanisms may be 
involved, including tetracycline's ability, to inhibit 
prostaglandin production, to suppress leukocyte activity 
and to function as scavengers of superoxide radicals. 
Chang and Houck (1970) reported that collagen breakdown 
products are chemotactic for polymorphonuclear leukocytes
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(PMNs). Galber and Creamer (1991) suggested that
suppressed collagenase activity in the gingival crevicular 
fluid of tetracycline treated individuals might also result 
from a decrease in oxidant-mediated activation of latent 
neutrophil collagenase. It was also suggested that
inhibiting the generation of arachidonic acid by blocking 
phospholipase A2 activity (Pruzanski et al., 1992), and
blocking the synthesis of prostaglandin E2 (PGE2) (El-Attar, 
Lin & Shultz, 1988) may be related to anti-inflammatory 
properties of the tetracyclines in the treatment of
disease.
1.8.6.2 Anti-collagenase activities of tetracyclines
The potential anti-collagenase activity of the 
tetracyclines was verified when Golub et al. produced a 
chemically modified tetracycline molecule (CMT) whose
antimicrobial efficacy was eliminated, but which did retain 
its ability to inhibit collagenase. They also noted the 
ability of tetracyclines to reduce diabetic gingival 
collagenase activity in germ-free rates (Golub et al., 
1983) . Because of these effects in germ-free rats, it was 
proposed that tetracyclines could inhibit extracellular 
collagenase by a mechanism independent of the drugs7 
antibacterial activity.
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Tetracyclines have been found to inhibit collagenases from 
different tissues and cellular sources, including PMNs 
(Golub et al., 1983, 1985a,b), macrophages (Maehara et al. ,
1988), osteoblasts (Ramamurthy et al. , 1993), chondrocytes
(Greenwald et al. , 1987), and tumor cells (Zucker et al. ,
1989) as well as extracts of human gingiva (Golub et al. ,
1990; Yanagimura et al. , 1989) and synovial tissue
(Greenwald et al., 1987).
Recent studies indicate that tetracycline inhibition of 
collagenase activity differs between different tissues and 
between cells from the same tissue, and, second, members of 
the tetracycline family of compounds may also differ in 
their anticollagenase effectiveness (Maehera et al. , 1988;
Lee et al. , 1991) . For example, clonal URM 106-01 rat
osteoblastic gelatinase is inhibited by exposure to 
tetracycline, whereas transformed rat osteoblastic 
osteosarcoma gelatinase is not sensitive to the drug 
(Vernillo et al., 1993). Furthermore, human
polymorphonuclear leucocyte collagenases are relatively 
sensitive to tetracycline inhibition compared with human 
fibroblast collagenases (Golub et al., 1991; Ingman et al., 
1993; Suomalainen, et al., 1992; Golub et al. , 1995).
Pharmacologic concentrations of minocycline (2 to 25 pg/ml) 
were found to inhibit crude collagenase extracted from 
human PMNs, whereas the collagenolytic activity of cultured 
human fibroblasts was resistant to this effect until
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extremely high concentrations of the drug were used (Golub 
et al., 1983, 1990; Maehara et al., 1988).
With regard to the fact that members of the tetracycline 
family differ in their ability to inhibit extracellular 
collagenase activity, Golub et al. (1985a) reported that
administration of minocycline or doxycycline to humans with 
periodontal disease appeared to inhibit collagenase in the 
periodontal pocket for a longer period of time than 
tetracycline. In addition Golub et al. (1991, 1992) and
Yangamura et al. (1989) also demonstrated that doxycycline
and minocycline are more potent than tetracycline HCL. 
Burns et al. (1989) confirmed the above result and proposed
that the greater effect of doxycycline was related to its 
stronger binding of the zinc cation at the active site of 
the enzyme.
Several studies have shown that tetracyclines act on both 
the latent and active forms of collagenase (Greenwald et 
al., 1987; Mcculloch et al., 1990; Lee et al., 1991).
So far, several mechanisms of action of these drugs have 
been identified including: a) their ability to block
already-active MMPs presumably by binding to the Zn2+ 
cation in the enzyme molecule. It has been suggested that 
tetracyclines bind to a secondary zinc (or Ca+2) cation not 
at an active site in the enzyme, resulting in a
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conformational change and loss of catalytic activity of the 
MMP (Lovejoy et al., 1994); b) their ability to prevent the 
oxidative activation of latent procollagenase and 
progelatinase secreted by several cell types (PMN 
leukocytes, osteoblasts) found in the periodontium (Lauhio 
et al., 1992; Ramamurthy et al., 1993); c) their ability to 
convert proenzyme to smaller inactive fragments; d) their 
ability to decrease synthesis of Pro-MMPs (Uitto et al., 
1994; Rifkin, Vernillo & Golub, 1993); e) their ability to 
protect endogenous MMP inhibitors (TIMP-1) (Sorsa et al. , 
1993) and other neutral proteinase inhibitors (al- 
antitrypsin) (Sorsa et al., 1993) from degradation and 
inactivation, because of reduced elastase activity in vivo. 
Elastase has recently been observed to degrade TIMPs (Okada 
et al. , 1988) . Tetracyclines might also prevent the
oxidative inactivation of TIMPs by reactive oxygen species 
such as HOCL (Lauhio et al. , 1992; Strickling & Hoidal
1992) ; f) their ability to contribute indirectly to 
inhibition of additional MMPs, i.e., stromelysin and 
elastase, which may not be directly inhibited by these 
drugs; g) their ability to enhance production of collagen 
(Schneir et al. , 1990; Sasaki et al. , 1992a) and bone
(Sasaki et al. , 1992b) when these processes are suppressed 
during disease such as in diabetes-induced skin lesions and 
periodontal ligament atrophy and osteopenia.
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1.9 AIM
With regard to the effects of tetracyclines on production, 
activity, and regulation of MMPs, and also the effects of 
locally delivered antibiotics in the clinical treatment of 
periodontal disease, it was decided to examine the effect 
of locally delivered antimicrobial systems, on the levels 
of stromelysin and TIMP in sites which did not respond to 
conventional treatment.
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CHAPTER 2 
MATERIALS & METHODS
2.1 Subj ects
Prior to the commencement of these studies ethical approval 
was obtained from the Glasgow Dental Hospital Ethics 
Committee. Subjects participating in these studies were 
informed of the protocol and consent was obtained. All 
patients taking part in the longitudinal investigation were 
free to withdraw from the study at any time.
The study population consisted of patients who had been 
treated by means of subgingival scaling and root planing 
but still displayed signs of persistent periodontal 
disease, defined as residual pocketing of >5 mm, with 
bleeding on probing (BOP) or suppuration. Fifty two 
subjects fulfilling the above criteria were selected from 
patients in the Department of Periodontology, Glasgow 
Dental Hospital and School. The subjects had no history of 
systemic disease which could influence the course of 
periodontal treatment. They were not on any medications 
that could influence the manifestations of periodontal 
disease, and they had not received antibiotic therapy 
within the past 6 months.
Thirty two of the subjects were female and twenty were 
male, with a mean age of 45, ranging from 30-67.
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2.2 Selection of periodontal sites
Site selection was carried out at a screening visit, after 
a full mouth periodontal examination using a CP-12 
periodontal probe (Ash, Densply, UK) . Four non-adjacent 
sites with periodontal pockets equal to or deeper than 5 mm 
with bleeding on probing or suppuration were selected. In 
order to increase the accuracy of the measurements taken 
and to simplify the harvesting of GCF, the buccal, 
anterior, mesial sites were preferred to the lingual, 
posterior, and distal sites.
2.3 Clinical design
2.3.1 Longitudinal study of the effects of
adjunctive locally delivered antibiotic 
therapy on matrix metalloproteinase and 
inhibitor in gingival crevicular fluid
The patients in this study were seen at the following 
visits: 1) screening visit, 2) baseline measurements visit,
3)treatment visit, 4) reassessment visit. At the screening 
visit, all study subjects signed an informed consent form. 
A full medical history was recorded, and a full periodontal 
examination was carried out. If the patient fulfilled the 
criteria, (section 2 .2) alginate impressions were taken of
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the upper and lower jaws, and an acrylic stent (Kombiplast, 
Dreve-Dentamid-GmbH) fabricated for attachment level 
measurements.
Oral hygiene instruction was given according to individual 
needs, but no periodontal instrumentation was carried out. 
10 days after the screening visit baseline measurements 
were taken in the following order:
1) Plaque Index (PI) (Silness and Loe, 1964) and Modified 
Gingival Index (MGI) (Lobene et al. , 1986) were recorded 
for the study sites.
2) GCF samples were taken from the study sites and GCF 
volume recorded with the periotron.
3) Bleeding on probing (BOP) and suppuration scores were 
recorded from the preselected sites.
4) The first set of pocket depth (PD) measurements was 
performed with the electronic pressure sensitive probe.
5) The first set of attachment measurements of the study 
sites was made with the acrylic stent and the electronic 
pressure sensitive probe.
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6) After changing the patient's position and removing and 
replacing the stent, the second set of pocket depth and 
attachment level measurements were carried out.
The study had a parallel design. The patients were
randomly allocated into four groups, three of which 
received scaling followed by a locally delivered
antimicrobial system. 6 weeks after the last treatment 
visit, patients were seen for a reassessment visit and the 
same measurements as at baseline were recorded.
2.4 Clinical measurements
One examiner (MR), carried out all clinical measurements 
throughout the study. The following parameters were 
recorded for the patients at baseline and at the 6 week 
visits. The order in which the measurements were taken, 
appears below.
2.4.1. Plague Index
The plaque index (PI) of Silness and Loe, (1964) was used 
for recording plaque accumulation. The scoring system is 
as follows:
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0 No plaque in the gingival area.
1 A film of plaque adhering to the free gingival 
margin and adjacent surface of the tooth. The 
plaque may only be noticed by running a probe 
across the tooth surface.
2 A moderate accumulation of soft deposits within 
the gingival crevice, on the gingival margin 
and/or adjacent tooth surface.
3 An abundance of soft matter within the gingival 
crevice and/or on the gingival margin and 
adjacent tooth surface.
The Plaque Index assesses very small differences in plaque 
accumulation (Lindhe, 1989). In this study, site scores 
refer to a single site PI recording.
2.4.2 Modified Gingival Index
The Modified Gingival Index (MGI) (Lobene et al. , 1986) was 
used to assess gingival inflammation and is described 
below:
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0 Absence of inflammation.
1 Mild inflammation; slight change in colour, 
little change in texture of any portion but not 
the entire marginal or papillary gingival unit.
2 Mild inflammation; criteria as above but 
involving the entire marginal or papillary 
gingival unit.
3 Moderate inflammation; glazing, redness, oedema, 
and/or hypertrophy of the marginal or papillary 
gingival unit.
4 Severe inflammation; marked redness, oedema and
or hypertrophy of the marginal or papillary 
gingival unit, spontaneous bleeding, congestion 
or ulceration.
The MGI was preferred to the more commonly used Gingival 
Index (Loe & Silness, 1963) because it provides greater 
sensitivity to the earliest changes of gingivitis as the 
lower part of the scale is expanded resulting in a scoring 
system of 0-4. Since bleeding upon probing is not a
criteria in the MGI, it is a completely non-invasive 
procedure. A non-invasive method was essential in this 
study since GCF samples were taken after the MGI scoring,
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and procedures which might irritate the gingival tissue and 
thereby alter the GCF constituent profile had to be avoided.
2.4.3 The gingival crevicular fluid sampling
method
Sample collection was performed in duplicate with a one 
minute interval, using filter paper strips and the fluid 
volume on the strip was measured immediately after 
sampling with a Periotron 6000 (Harco Electronic, Winnipeg, 
Canada).
In the clinic, GCF was sampled after the PI and MGI scores 
were taken but before any other clinical recordings which 
could cause irritation of the tissues and serum 
contamination of the sample.
The site to be sampled was isolated with cotton wool rolls 
and supragingival plaque was carefully removed. The region 
was dried with a gentle air stream and 3 0 second (s) later 
GCF was collected with a Whatman grade 4 paper strip 
(Whatman Labsales Ltd., Maidstone, Kent)(2x13 mm) 
(Griffiths et al. , 1988) inserted into the crevice until
mild resistance was felt and left there for 30 secend 
(Figure 2.1). Strips visually contaminated with saliva or 
blood were discarded. The sampling method is reliable and
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Figure 2.1 Gingival crevicular fluid sampling
causes no significant disturbance of the gingival blood 
vessels (Gustafsson et al., 1992) . The fluid volume on the 
strip was measured immediately after sampling with a 
Periotron 6000 GCF (Harco Electronic, Winnipeg, Canada) 
(Figure 2.2) . The jaws of the periotron were wiped with 
pure ethanol and then dried between readings. The strips 
were then placed in individual sterile tubes and stored at 
-30 centigrade degree (°C) until further processing was 
carried out. Subsequently, the strips were eluated into 
500 microlitres (pil) of incubation buffer at room 
temperature using a rotary mixer. The strips were then 
discarded and the elute aliquoted in sterile tubes and 
stored at -3 0°C. These aliquots were subsequently analysed 
for the quantification of SL and TIMP.
2.4.4 Bleeding on probing
The Florida Probe was used to assess bleeding upon probing 
at the same time as the first set of probing pocket depth 
measurements. BOP scoring was carried out within 3 0s of 
probing.
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2.4.5 Suppuration
A ball burnisher was used to apply gentle pressure on the 
gingival wall of the periodontal pocket in an apico-coronal 
direction in order to determine the presence or absence of 
suppuration.
2.4.6 Probing depth and attachment level
assessments
In this study pocket depth and attachment level (AL) were 
recorded to the nearest 0.2 millimetre (mm) using the 
Florida probe (Florida Probe Corporation, Florida, USA) 
(Gibbs et al. , 1988) . The Florida Probe is an electronic
pressure sensitive probe with a constant force of 20 gram 
(g). The system consists of a pocket depth and an
attachment level ('stent') handpiece, a foot switch, a 
computer interface and a portable personal computer (Figure 
2.3). When the foot switch is pressed, the measurements of 
PD and AL are made electronically, using the 'pocket depth' 
and 'attachment level' stent. Measurements were recorded 
by an assistant from the computer screen, as the operator 
was blind to the measurement. The probe tip has a diameter 
of 0.4 mm, no visible graduations along its length and it 
reciprocates through a sleeve. The edge of the sleeve is 
the reference from which measurements are recorded. As
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Figure 2.3 Florida probe; consists a computer interface
and a portable personal computer, a foot switch, pocket depth 
and an attachment level ('stent') handpiece
identification of the cemento enamel junction (CEJ) is 
often complicated by its subgingival location or the 
presence of restorations, the following method of recording 
attachment level measurements was used. A fixed reference 
point is required for attachment level measurements. The 
Florida probe 'stent' handpiece has a 2 mm diameter collar 
at the edge of its sleeve which, during attachment level 
measurement, is seated on a custom made hard/soft acrylic 
stent (Kombiplast, Dreve-Dentamid-GmbH) covering the crowns 
of the teeth. These stents were constructed for both upper 
and lower arches for each patient from a 2 mm thick 
silicone layer using a modification of the method described 
by Isidor, Karring and Attstrom, (1984) . The stents were 
made on individually cast models using a vacuum forming 
unit. The stents were then trimmed to cover approximately 
the coronal one third of the crowns of the teeth at the 
sites selected for the study. At other sites as much as 
possible of the stent was preserved in order to assist 
location and retention. Using an inverted cone bur and a 
low speed handpiece grooves approximately 1 mm deep, 2 mm 
wide and 1 mm high were cut, about 1 mm away from the 
apical edge of the stent, at the sites to be used in the 
study. The grooves were then marked with a permanent pen 
for ease of identification. The disc of the probe 
handpiece was located in these grooves during AL 
measurements. Attachment level was recorded relative to 
the point at which the probe handpiece disc was seated on
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Figure 2.4 Attachment level measurement using the Florida 
probe and occlusal stent
Figure 2.5
probe
Probing depth measurement with the Florida
the stent (Figure 2.4) . The grooves on the stent were 
located to record interproximal AL at the mid point between 
the contact point and the adjacent line angle.
PD was assessed by using the point at which the probe 
sleeve was brought into contact with the gingival margin 
and was at the same point as the measurement was recorded 
(AL recording) . Care was taken to ensure that the probe 
tip was held parallel to the long axis of the tooth (Figure 
2.5) .
PD and AL measurements were taken in duplicate. After the 
first set of measurements was obtained, the stents were 
removed, the patient's position was changed, and the 
examiner changed his position by leaving the examination 
room. For the second set of measurements all the
procedures were repeated.
2.5 Clinical treatment
A single operator (NP), performed all the clinical 
treatment throughout the study. At the treatment visits 
each group received one of the following treatments:
1) Subgingival scaling and root planing under local
anaesthesia followed by application of 0.5 mm diameter
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ethylene vinyl acetate copolymer fibres containing 25% 
tetracycline hydrochloride (Actisite, ALZA, corporation, 
Palo Alto, CA), into the pocket (Figure 2.6).
2) Subgingival scaling and root planing under local 
anaesthesia followed by application of 2% minocycline 
hydrochloride ointment (Dentomycin, Cyanamid international, 
Lederle Division, Wayne, NJ) into the pocket (Figure 2.7).
3) Subgingival scaling and root planing under local 
anaesthesia followed by application of metronidazole 25% 
dental gel (Elyzol, Dumex, Denmark) into the pocket (Figure 
2 .8) .
4) The control group received only subgingival scaling and 
root planing under local anaesthesia.
At each visit the treated sites were examined for any signs 
of tissue reaction. The patient was asked whether any 
symptoms had been noted. 42 days post treatment all the 
baseline measurements were repeated for each patient. 
During this study other sites received conventional 
maintenance care.
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Figure 2.6 Tetracycline fibre and cyanoacrylate adhesive 
(Actisite)
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2.5.1 Application of tetracycline fibre
Tetracycline fibre is a 0.5 mm diameter fibre made of 
ethylene vinyl acetate copolymer, which is loaded 25% by 
weight with tetracycline hydrochloride. The fibre contains 
0.5 milligram (mg) tetracycline per centimetre (cm). One 
fibre comprises of 12.7 mg tetracycline hydrochloride and
38.1 mg of ethylene/vinyl acetate (VA) copolymer (40% VA). 
Initially, subgingival scaling and root planing was 
performed under local anaesthesia for all pockets (except 
for 1 untreated control) and fibres were placed in the 
study sites. The fibre was wrapped one turn loosely around 
the entire periphery of the tooth and pushed down to the 
base of the periodontal pocket by passing it through the 
contact points using dental floss or a plastic instrument. 
The remaining part of the pocket was filled with the fibre 
using, a back-and-forth layering technique, up to the 
gingival margin without creating excessive tension in the 
soft tissues. The length of fibre applied was recorded. 
Any excess fibre was cut off and discarded (Figure 2.9).
A cyanoacrylate adhesive (Octyldent, TRI-Point Medical L.P 
Raleigh N.C) was applied along the gingival margin, 
covering the top layer of the fibre and a periodontal 
dressing (Coe-Pak, GC America INC. Chicago, IL) was placed. 
The fibre was removed 10 days later. The average length of 
fibre required was 11.51 centimetre per tooth (range 5-23
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Figure 2.9 Application of tetracycline fibre
cm/tooth, depending on tooth type) and the average time 
required to place the fibre was 8.23 minute per tooth 
(range 5-2 0 minutes, depending on tooth type).
2.5.2 Application of minocycline gel
Minocycline (Dentomycin, Cyanamid international, Lederle 
Division, Wayne, NJ) is a yellow ointment formulation which 
contains 2% minocycline hydrochloride and is applied into 
the pocket via a disposable applicator, once every 14 days 
for 3 treatments. Since the material is unstable at room 
temperature, the applicators were kept in a refrigerator 
until 20 minutes before use.
After subgingival scaling and root planing under local 
anaesthesia, the minocycline dental gel was applied to the 
pocket until it was overfilled (Figure 2.10). The excess 
was removed using cotton pellets. The average time 
required to apply the gel was less than 1 minute per tooth. 
This medication was repeated 14 days and 28 days after the 
initial application.
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Figure 2.10 Application of minocycline gel
2.5.3 Application of metronidazole gel
Metronidazole dental gel (Elyzol, Dumex, Denmark) is a 
white semisolid suspension containing 25% metronidazole 
benzoate in a mixture of glyceryl mono-oleat (GMO) and 
triglyceride (sesame oil) . It is dispensed in a cartridge 
containing 1 g of gel corresponding to 250 mg metronidazole 
per g and is injected into the pocket using an 
intraligamentous injection syringe with a blunt needle. 
After subgingival scaling and root planing under local 
anaesthesia, the metronidazole dental gel was applied into 
the pocket until it was overfilled. The excess was removed 
using cotton pellets. The average time required to apply 
the gel was less than 1 minute per tooth. The application 
was repeated 7 days later.
2.5.4 Scaling and Root planning
The control group received only subgingival scaling and 
root planing under local anaesthesia. In an effort to 
standardise the scaling for the patients approximately 5 
minutes scaling per tooth was allowed.
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2.6 Experimental Materials
2.6.1 Whatman grade 4 paper strips
The Whatman grade 4 paper strips (Whatman Labsales Ltd. , 
Maidstone, Kent) were cut manually to a standard site, 13 
mm in length and 2 mm wide, using a steel ruler and 
scalpel. A line was drawn on each strip at 8 mm, 
indicating the length of paper strip to be inserted between 
the periotron jaws and that part of the strip to be used 
for GCF sampling. Rubber gloves were worn during their 
preparation in order to avoid contamination of the strips 
by substances from the operators hands. The strips were 
then placed in glass universal bottles for autoclaving and 
storage.
2.6.2 ELISA buffers and reagents
The buffers employed were as followings:
1) Coating buffer (CB) : 1.59g Na2CC>3., 2.93g NaHC03 was
dissolved in 800 ml distilled H20. The pH was adjusted to
9.6 at just under 1 litre, by adding 1M HCl up to 1 litre 
in a volumetric flask. It was stored in a sterilised 
bottle at 4°C for a maximum of 1 week.
64
2) Incubation buffer (IB) : 8g NaCl, 0.2g KH2P04/ 1.44g
Na2HP04. 2H20, 0.2g Kcl, 0. 5g Tween 2 0 (SIGMA chemical
company Ltd., Poole, Dorset) dissolved in 800 millilitre of 
distilled H20, and made up to 1 litre with the addition of 
lg of lyophilised bovine serum albumin (BSA) (SIGMA, St. 
Louis, USA) . This layered on the surface without mixing. 
It was stored at 4°C for a maximum of 1 week (pH 7.4) .
3) Wash buffer (PBST): This was prepared at 10 times the 
concentration of incubation buffer (nil BSA) and stored at 
room temperature (RT) . It was diluted 1/10 immediately 
before use.
4) Phosphate buffered saline (PBS): PBS was prepared by
dissolving 8g NaCl, 0. 2g NaCl, 0. 2g KH2P04, 0.2g Kcl, 1.44g
NaH2P04 . 2H20 up to 1 litre of distilled water (pH 7.4).
2.6.3 Antibodies and purified standards for
ELISAs
The antibodies which were used in the ELISA included: Mac 
78 anti-stromelysin monoclonal antibody and rabbit anti- 
stromelysin polyclonal antibody, Mac 19 and Mac 15 anti- 
TIMP monoclonal and purified recombinant human stromelysin 
(SL) and also tissue inhibitor of metalloproteinases (TIMP) 
were donated by Cell Tech. Ltd. Slough, UK. Donkey anti
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rabbit-HRP conjugated IgG was purchased from Jackson 
Immuno-research Laboratories, Avondale, PA, USA.
2.7 Experimental Methods
2.7.1 Calibration of the periotron 6000
for use in clinical trials
In order to transform the Periotron digital readings for 
each paper strip into volumes, and also to verify the 
accuracy of the instrument the following procedure was 
carried out. First the blank periopaper was placed between 
the jaws of the machine and the reading dial was set to 
zero. Known volumes of PBS plus serum (in equivalent 
volume) were delivered to Whatman grade 4 paper strip with 
a Hamilton microsyringe at a range of volumes (0.05-1 jil) 
and Periotron readings taken. Each measurement was 
performed 3 times. The mean value for each volume was used 
in a linear regression analysis, from which the slope and 
intercept were used to determine the volumes of the GCF 
collected. The curve was analysed in two separate lines 
(fitted by regression method) as shown in Figure 2.11. The 
upper portion included volumes of 0.2, to 1 |il whereas the 
lower portion included volumes of 0.05, to 0.2 pil. The 
calibration was performed each day samples were taken, in
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Figure 2.11 Calibration curve of the Periotron 6000 at
the volume range of 0.05 to 0.2 \il and 0.2 to 1 fil. Each 
point represents the mean of three measurements.
a= the intercept
b= the volume coefficient
r= Pearson correlation coefficient
order to reduce daily variability and thus improve
accuracy.
2.7.2 Gingival crevicular fluid elution
GCF samples were eluated in 500 jj.1 of incubation buffer for 
1 hour at room temperature using a rotary mixer. The 
strips were then discarded and the elutes were aliquoted 
and stored at -30°C, until further procedures. Previous 
studies (Haerian, 1994) demonstrated that the elution of
GCF samples in 500 p,l of incubation buffer would yield
concentrations in the eluate within the precision range of 
each ELISA.
2.7.3 Sandwich ELISA methodology
The sandwich ELISA method was a modification of the 
technique described previously by Cooksley et al. (1990). 
The modifications used were as follows: a) the sample
volume in each well was reduced from 200 |il to 50 (il; since 
we diluted the samples in 500 pil of incubation buffer and 
required sufficient volume for two different ELISAs and at 
the same time some back up volume; b) all the paper strips 
were eluated in the incubation buffer; since we had to use 
the elute from the same paper strip for different ELISAs it
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antibody
Adding standard/ 
sample antigen
Incubating with 
second antibody
<
4
Adding HRP-anti- 
rabbit IgG/Extr- 
Avidin Peroxidase
Figure 2.12 Sandwich ELISA: basic principles 
HRP: horseradish peroxidase
i
was impossible to use two different assay buffers to elute 
each individual paper strip; c) the calibration line was 
altered toward the lower concentration, based on the range 
of absolute amounts of SL and TIMP detected in preliminary 
experiments.
This method assays the amount of antigen present in the 
sample as directly proportional to the amount of the second 
antiserum (rabbit), which was quantified indirectly by the 
addition of horse radish peroxidase (HRP) conjugated anti­
rabbit IgG (donkey) (Jackson Immuno-research Laboratories, 
Avondale, USA) resulting in high optical densities (ODs) 
for high antigen concentration.
The results of experiments already carried out in our 
labratory (Haerian, 1994) demonstrated that among five 
different types of Immulon microplates (Dynatech 
Laboratories), the Immulon IV plates showed the least 
variability for the sandwich ELISAs. In summary, (Figure 
2.12), the 96-well polystyrene microplate (Immulon 4 
Dynatech Laboratories, Billingshurst, Sussex, U.K) was 
coated with the first antibody, specific to the antigen to 
be quantified. The eluate of the sample was then added and 
any antigen present was captured by immobilised antibody. 
The plate was then incubated with a biotin-conjugated 
second monoclonal antibody. Finally the plate was 
incubated with Extr Avidin-Peroxidase (Sigma).
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Table 2.1 Steps and reagents for stromelysin (SL) and 
tissue inhibitor of metalloproteinase (TIMP) sandwich 
ELISAs.
Sandwich ELISAs
Steps Reagent
1. Wash thrice with 200 |il/well 
CB
2. Coat with 50 nl/well specific 
antiserum. Incubate overnight at 
4°C.
3. Wash with approximately 200 
fxl/well PBST, 4x4+1 times and 
dry. This Removes excess and 
loosely coated antibody.
4. Add 100 (il/well IB for 1 hr 
at RT to block the free sites.
5. Wash with approximately 200 
|il/well PBST, 4x4+1 times and 
dry.
6. Add 50 |al/well standard 
antigen or eluted samples in 
duplicate. Incubate for 1 hr on 
the shaker at a speed of 100, at 
RT.
7. Wash with approximately 200 
fil/well PBST, 4x4+1 times and 
dry. This Removes free and 
loosely-bound antigen.
8. Add 50 jil/well second 
antibody incubate for 1 hr on the 
shaker with speed 100, at RT.
9. Wash with approximately 200 
|il/well PBST, 4x4+1 times and 
dry. This Removes free and 
loosely-bound antibody.
10. Add 50 fil/well Extr Avidin 
peroxidase for TIMP and HRP 
conjugated Anti-rabbit IgG for 
SL. Incubate for 1 hr on the 
shaker at a speed of 100, at RT.
11. Wash with approximately 200 
fil/well PBST, 4x4+1 times and 
dry. This Removes of conjugated 
Anti-rabbit IgG.
12. Add 50 nl/well TMB. 
Incubate for 20 min. On the 
shaker at a speed of 100, at RT.
13. Add 50 fil/well NaF to stop 
colour development.
14. Read at 630 nm on a plate 
reader.
Mac 78 anti-SL and Mac 15 
anti-TIMP.
Recombinant SL and TIMP 
served as standard 
antigens.
Biotin-Mac 15 anti-TIMP 
and Rabbit anti-SL
Extr Avidin Peroxidase: 
1/5000 in IB for TIMP 
HRP: 1/20000 in IB for 
SL.
CB=Coating buffer PBST=Wash buffer TMB=Peroxidase substrate 
IB=Incubation buffer RT=Room temperature HRP=Horse Radish Peroxidase
Visualisation was achieved by incubation with 
tetramethylbenzidine (TMB) substrate, and the reaction 
stopped with 2.5% Sodium fluoride (NaF). The plate was 
read at 63 0 nm on a Dynatech MR5000 plate reader. The 
method is described in detail in Table 2.1. Serial 
dilutions of standard antigen were run for each plate. The 
working range of the standard antigen for the stromelysin 
and TIMP was 12.5-0.025 nanogram per millilitre (ng/ml) in 
incubation buffer (IB) and their optical densities (ODs) 
were used in a linear regression analysis from which the 
slope and intercept were used to determine the level of SL 
and TIMP in the samples. The precision range was defined 
as the linear part of the working range. The typical 
standard curves (precision ranges) of the SL and TIMP 
sandwich ELISAs were 6.25 to 0.05 (Figure 2.13). The least 
squares method was used to plot the best fitting line and 
r2>0.99 were obtained for all assays. Linear functions of 
the type lognOD=a+bx (lognc) , where OD=Optical density, 
c=concentration, a=the intercept and b=the lognc 
coefficient were thus produced, and used for the 
determination of sample antigen quantities. A similar 
standard curve was generated and a new line fitted each 
time an assay was run.
The central wells were used on each plate for standards or 
samples in order to avoid the edge-effect (Tijssen, 1985). 
The peripheral wells were used for assaying the controls
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Figure 2.13 Typical calibration curve for (a)
stromelysin (SL) and (b) tissue inhibitor of 
metalloproteinase (TIMP)
(except for the control 14) (Table 2.2), and were run in 
duplicate. Zero antigen wells (Controls 14) were run in 
quadruplicate. Control wells (control 14, Table 2.2) in 
the central wells in each plate were included which 
contained no sample or standard antigen, in order to 
calculate background binding.
The mean plus two standard deviations (SD) of this 
background reading were taken as the cut-off point for 
detectability (Tijssen, 1985).
2.7.3.1 Stromelysin and TIMP ELISA
SL and TIMP quantification was performed on the eluates of 
GCF, and all constituents were assayed by means of sandwich 
enzyme linked immunosorbent assays (ELISA), based on a 
modification of the method of Cooksley et al. (1990). The
96-well polystyrene microplate (Immulon 4 Dynatech 
Laboratories, Billinghurst, Sussex, U.K) was coated with 
the first antibody, specific to the antigen to be 
quantified. These antibodies were Mac 78 anti-stromelysin 
monoclonal antibody for SL and Mac 19 anti-TIMP monoclonal 
antibody for TIMP. After overnight incubation at 4°C, 
these were washed, blocked and incubated with serial 
dilutions of recombinant human stromelysin and TIMP. The 
GCF samples were then eluted in an incubation buffer
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Table 2.2 Control tests for sandwich ELISAs. Standard was 
added at a fifth concentration of the standard curve. When 
the addition of a reagent was omitted the equivalent volume 
of the respective buffer alone was added.
Control Step
First Standard Second HRP/Extr
antibody antibody Avidin
coating (Antiserum) Peroxidase
1. - - - -
2. + - - -
3. - + - -
4. - - + -
5. - - - +
6. + + - -
7. + - + -
8. + - - +
9. - + + -
10. - + - +
11. - - + +
12. + + + -
13. + + - +
14. + - + +
15. + + +
containing 0.1% protease-free bovine serum albumin (BSA) 
(Calbiochem) , for one hour at 25°C with constant mixing. 
The plate was then incubated with a biotin-conjugated 
second monoclonal antibody or HRP-conjugates rabbit-anti-SL 
in the case of SL in the same buffer for one hour at 25°C 
with constant mixing. Biotinylated Mac 15 antibody was 
used to reveal TIMP. The plate was washed and incubated 
with HRP-anti-rabbit IgG (Jackson) in the stromelysin assay 
and Extr Avidin-peroxidase (Sigma) in the TIMP assay in the 
same buffer for one hour at 25°C with constant mixing.
Visualisation was achieved by incubation with 3,3',5,5'- 
tetramethylbenzidine ('TMB) (KPL) for 15 minutes at 25°C 
with constant mixing and the reaction stopped with 2.5% NaF 
(Sodium fluoride) . The plate was read at 630 nm (dual 
wavelength with 490 nanometre as reference wavelength), on 
a Dynatech MR 5000 plate reader. Serial dilutions of 
standard were run for each individual plate and their ODs 
used in a linear regression analysis from which the slope 
and intercept were used to determine the sample 
concentration of SL and TIMP (Figure 2.13).
Results were expressed as picogram per 30 second (pg/30s) 
sample. Two wells in each plate had no sample or standard 
antigen so as to calculate background reading. The mean 
plus two standard deviations of this background reading was
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taken as the cut-off point for detectability (Tijssen, 
1985) .
2.8 Preliminary experiments
The results of experiments already carried out in our 
laboratory (Haerian, 1994) demonstrated that:
a) Among five different types of immulon (Dynatech 
Laboratories) microelisa plates, the immulon plates were 
selected for the sandwich ELISAs in these studies.
b) There was no significant difference between the levels
of GCF components on different plates at the same
concentration and the intra-plate variability was low for 
levels of SL and TIMP GCF.
c) Serum components did not interfere in the assaying of 
GCF SL and TIMP.
d) GCF SL and TIMP respond in a similar way to the highly
purified standard and it was concluded that the assays 
developed could be used for their quantification in GCF.
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e) The elution of GCF samples in 500|il of incubation 
buffer would yield concentrations in the eluate within the 
precision range of each ELISA.
f) The SL and TIMP sandwich ELISAs described by Cooksley 
et al. (1990) were modified.
2.8.1 The reproducibility of stromelysin (SL) and
tissue inhibitor of metalloproteinase 
(TIMP) on gingival crevicular fluid paper 
strip samples
This part of the study was designed to determine the 
reproducibility of stromelysin (SL) and tissue inhibitor of 
metalloproteinase (TIMP) sampled from gingival crevicular
fluid (GCF), and recovered on filter paper strips. A total 
of 310 sites from 52 patients were sampled in duplicate. 
The first and second samples were taken with a 1 minute 
interval between. The sampling of the same sites was
repeated after treatment, resulting in a total of 620 pairs 
of samples (1240 samples).
The GCF SL was detectable in 180 (38%) out of 620 sites in
the first set of samples, and 150 (24%) out of 620 sites in
the second set of samples. The mean level of GCF SL was 
higher in the first samples than the second samples.
73
However, the paired t-test failed to demonstrate a 
significant difference when the first and second samples 
were compared for their GCF SL levels (p=0.18)(Table 3.3).
TIMP was detected in 615 (99%) of the first samples, and
597 (96.2%) out of 620 sites of the second samples. The
mean level of GCF TIMP decreased significantly in the 
second sample compared to the first sample. The paired t- 
test demonstrated a significant difference when the first 
and second samples were compared for their GCF TIMP levels 
(p<0.001) (Table 3.3).
Correlation between the first and second samples was 0.22 
(p<0.001) and 0.20 (p<0.001) for the SL and TIMP levels
respectively. The correlation between the GCF volumes of 
the first and second samples was 0.62 (p<0.001).
Methodological considerations
Several investigators have shown the first sample to be the 
richest in the components to be measured (Lamster et al., 
1989; Persson & Page 1990) . Other investigators have 
discarded the first sample, or used it to measure volume, 
and used subsequent samples for analysis (Binder et al., 
1987; Larivee et al., 1986). Binder et al. (1987)
harvested repeated samples of GCF and measured fluid volume 
and total content and concentration of alkaline and acid
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Table 2.3 Comparison of Mean (SEM) GCF level of SL, TIMP 
and volume in the first sample and second sample(n=620) , 
using Paired t-test.
GCF SL GCF TIMP GCF volume
First samples 10.37(1.23) 359.9 (16.1) 0.432 (0.01)
Second samples 8.77 (0.75) 138.79(7.13) 0.272 (0.01)
p value 0.18 <0 . 001 <0.001
phosphatase activities. They concluded that the first 
sample harvested should be discarded and analysis performed 
on second or later replicate samples. Our observations do 
not confirm the model of GCF flow and composition suggested 
by Binder et al. The differences in our observations and 
those of Binder et al. (1987) may result from differences
in sampling technique or in the enzymes measured. GCF 
contains many enzymes of differing molecular size and 
concentration; one might expect the kinetics of 
accumulation of enzymes on filter-paper strips, to differ 
one from another, and also we measured the amount of 
antigenic enzyme whereas they measured the activity of 
enzyme.
The fluid component of GCF arises from the vessels of the 
microcirculation of the gingiva, and traverses the inflamed 
tissue during which it picks up enzymes being released from 
diseased tissue; the enzyme containing fluid enters the 
reservoir in the pocket or sulcus where enzymes become more 
concentrated. It is not supposed that over a short time 
period of seconds or minutes, the rate of production of 
stromelysin from the fibroblast cells, the rate of release 
of stromelysin from the tissues, the rate of passage of 
fluid from blood vessels to the fluid reservoir and the 
exit of fluid from the reservoir, to be in a steady-state 
of equilibrium. The first sample may deplete entirely or 
in part, the enzyme-rich reservoir during the 30 seconds.
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The fluid that replenishes the reservoir is less enzyme- 
rich, and replicate sampling, especially with short time 
intervals, may result in a washout of enzyme from the 
disease-active tissue, at least in the short term, when 
samples are taken at a 1 minute intervals.
It is concluded that the first sample should be preferred 
to the second GCF sample. This may be particularly
important for the assessment of GCF TIMP.
2.9 Statistical Analysis
The data were analysed using the Minitab version 9.2 and 
the SPSS/PC+ statistical packages. The study of GCF
stromelysin and tissue inhibitor of metalloproteinases in 
gingival crevicular fluid was carried out to evaluate the 
changes of the GCF levels of SL and TIMP after treatment 
with three different locally delivered antibiotics plus 
scaling and root planing or scaling and root planing alone 
as a control treatment. Furthermore, the study was planned 
to assess the ability of GCF SL and TIMP to predict further 
response to the treatment. First, the distribution of the 
data was inspected using histograms, and it was found that 
the data had a markedly skewed distribution. While, log 
transformation (log10 (1+x), x=original data value) was not 
successful in producing a normal distribution in SL data,
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it was successful in TIMP data. Therefore, parametric 
tests were utilised for TIMP and non parametric tests were 
performed for SL.
The comparisons were made between sites with bleeding on 
probing (BOP) versus (vs.) sites without BOP, between 
suppuration sites vs. sites without suppuration. Moreover, 
the diseased sites were broken down according to the 
smoking status, gender, age and site position (anterior vs. 
posterior sites) and the two sample comparisons, were made
using the Mann-Whitney U test for SL and the two sample t-
test for TIMP. Comparison of sites with different MGI was 
made using the Kruskal-Wallis test. The Spearman rank 
correlation coefficients were calculated to examine the 
relationship between biochemical parameters and pocket 
depth or GCF volume. Discriminant analysis was performed 
to disclose the clinical characteristics of sites with 
different levels of GCF SL or TIMP.
Analysis of the clinical findings was performed using both 
site and patient as the experimental unit. When the 
subject was considered as the unit, sites within each
subject were averaged and one score produced per subject 
for each clinical and biochemical parameter. The mean
detection limit of the ELISA assay was divided by two and 
was used as the SL and TIMP levels for the sites at which 
these biochemical components were not detected.
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The principal criteria of response to the treatment were 
changes in level of GCF SL and TIMP, in this study. The 
mean differences were utilised for the analysis of SL and 
TIMP in terms of response to the treatments. Histogram 
showed normal distribution after log transformation, 
therefore, parametric analysis were performed. The
analysis of the effect of treatment on the biochemical and 
clinical parameters was performed as follows; For each 
treatment group the changes in the GCF SL and TIMP and
clinical parameters were calculated and subjected to the
paired t-test. Analysis of variance (ANOVA) was employed on 
the log transformed data in order to determine significant 
differences in the changes in GCF levels of SL and TIMP 
between different treatments. When a significant effect 
was detected by the use of ANOVA, follow up analysis was
performed using Tukey's test in order to determine the
direction and location of the differences. The analysis of 
covariance (ANCOVA) was used with the baseline SL or TIMP 
levels as continuous covariantes. By using the ANCOVA, the 
variability among the sites and treatment groups which 
existed at the baseline levels of GCF SL and TIMP was taken 
into account mathematically. If a significant difference 
was found between treatments, then the post-hoc comparisons 
were performed by comparing only two groups at a time. The 
probability threshold for statistical significance was set 
at 0.020 (0.05/V6, where 6=number of comparisons, Brown &
Swanson Back, 1988) .
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The effects on GCF SL and TIMP changes of factors such as 
smoking status, gender, age and site position were analysed 
using the two sample t-test. The correlation between the 
post-treatment levels of biochemical and clinical 
parameters were examined by the non-parametric Spearman 
rank correlation coefficients.
The General Linear Model (GLM) procedure, which performed 
analysis of variance for unbalanced data, was used to find 
out if there were statistically significant differences in 
the changes of stromelysin levels, taking into account the 
effect of other potentially important factor such as pocket 
depth, smoking status, the location of site, age, and sex.
In order to examine the ability of the GCF SL and TIMP 
baseline levels to predict the treatment outcome, 
(regardless of treatment type) two extreme categories of 
sites were selected as the best responding sites (BRS) and 
the worst responding sites (WRS). The criteria for 
selection were; WRS: PD>3.5 plus BOP at the reassessment,
BRS: PD<3.5 and no BOP at the reassessment visit. The WRS 
and BRS categories were than compared using the Mann- 
Whitney U test. Moreover, the difference between WRS and 
BRS on changes in their biochemical profile and GCF volume 
(ASL, ATIMP and AVol) were accomplished using the two 
sample t-test on the log10 transformed data. Finally, a 
similar analysis was performed on another two extreme
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categories. The criteria for these categories were: a)
sites which showed attachment gain>l mm b) sites which 
showed attachment loss (AAL<0).
In the study of repeated sampling of stromelysin (SL) and 
tissue inhibitor of metalloproteinases (TIMP) from gingival 
crevicular fluid, SL and TIMP were assessed in the same 
samples and results were expressed as absolute amounts i.e. 
pg/3 0s of sample collection. The differences in the 
stromelysin levels of each site between the first and the 
second sample were subjected to paired t-test.
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CHAPTER 3 
RESULTS
3.1 A cross-sectional analysis of the
association between GCF SL and TIMP 
levels and clinical parameters
A total of two hundred and six sites with recurrent 
periodontitis from 52 patients were sampled. Two diseased 
sites were excluded for technical reasons, one site lost 
its tetracycline fibre before the 10 day placement period 
finished and in the scaling group a further site could not 
measured. Within each patient, 4 diseased sites were 
selected. The logarithmic transformation failed to produce 
a normal distribution of data for SL, but was successful 
with TIMP at the baseline. Therefore, non-parametric tests 
(Mann-Whitney U test) for SL and parametric tests (two 
sample t-test) for TIMP were performed at the baseline. 
The relationship of biochemical parameters with pocket 
depth and GCF volume were examined with Spearman rank 
correlation. The relationship of biochemical parameters 
with pocket depth and GCF volume were performed with 
Spearman rank correlation.
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3.1.1 Comparison of GCF levels of stromelysin and
TIMP between bleeding and non-bleeding 
sites, suppurating and non-suppurating sites 
and sites with different levels of gingival 
inflammation at the baseline
SL was detectable in only 61 (29.6%) out of 206 sites. The 
level of SL was higher in sites with bleeding on probing 
(n=185), than sites which did not bleed on probing (n=21), 
however the difference was not statistically significant 
(p=0.47) (Table 3.1). The level of SL was lower in sites 
with suppuration (n=27), than sites without suppuration 
(n=179) but the difference was not significant (p=0.36) 
(Table 3.2) . The level of SL increased with increasing
gingival inflammation scores and the Kruskal-Wallis test 
showed this difference was significant (p=0.028) (Table 
3.3).
TIMP was detected in 203 (98.5%) sites. The TIMP level was 
lower in bleeding sites versus non-bleeding sites, however 
it was not statistically significant (Mann-Whitney U test
p=0.62) (Table 3.1). The TIMP level was higher in
suppurative sites (n=27) compared to the sites which did
not show suppuration (n=179) , but this difference was not 
significant (p=0.12) (Table 3.2). No relationship was 
observed between different gingival inflammation scores and 
GCF TIMP level (p=0.395) (Table 3.3).
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Table 3.1 Comparison of GCF SL and TIMP levels in sites 
with bleeding on probing (BOP) and sites without bleeding 
on probing at the baseline, using Mann-Whitney U test for 
SL and two sample t-test for TIMP (n=206). Mean & (SEM) 
are given.
n Stromelysin(pg/30s) TIMP(pg/30s)
Negative BOP 21 18.57 (5.12) 322 (110)
Positive BOP 185 20.59 (2.47) 291.2 (25.2)
p value 0.47 0.62
Table 3.2 Comparison of GCF SL and TIMP levels in sites 
with suppuration and sites without suppuration at the 
baseline, using Mann-Whitney U test for SL and Two sample 
t-test for TIMP (n=206). Mean & (SEM) are given.
n Stromelysin(pg/30s) TIMP(pg/30s)
Negative
Suppuration
179 21.09 (2.59) 281.1 (26.8)
Positive
Suppuration
27 15.69 (2.60) 381.9 (71.1)
p value 0.36 0 .12
3.1.2 Correlation between probing depth, GCF
volume and GCF levels of matrix 
metalloproteinases and their inhibitor
The correlation of SL and TIMP with the probing depth and 
GCF volume is shown in Table 3.4. Overall, SL and TIMP's 
correlation with pocket depth and GCF volume were either 
weak or not significant.
3.1.3 Comparison between GCF level of SL, TIMP,
and GCF volume, considering smoking, 
gender, age and anterior vs. 
posteriorsites
The effect of smoking on the level of GCF SL, TIMP and 
volume in diseased sites were compared. Results showed 
that the level of GCF SL, and GCF volume were lower in 
smokers than non-smokers in the diseased sites whereas the 
mean level of TIMP was higher in these sites in smokers 
than non smokers. However, none of the differences were 
significant (p value for SL=0.22, TIMP=0.34, Vol=0.39)
(Table 3.5).
The effects of sex, age, and site on GCF SL, TIMP and 
volume in 206 periodontitis sites were evaluated using 
Mann-Whitney U test for SL and two sample t-test for TIMP
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Table 3.3 Comparison of GCF SL and TIMP levels for
different gingival inflammation scores at baseline, using
Kruskal-wallis test for SL and ANOVA test for TIMP
(n=206) . Mean & (SEM) are given.
n Stromelysin(pg/30s) TIMP(pg/30s)
MGI = 0 6 16.70 (4.12) 296 (115)
MGI=1 29 11.50 (1.03) 234.0 (53.2)
MGI=2 112 18.64 (2.28) 326.1 (38.9)
MGI=3 59 28.45 (6.53) 263.4 (38.1)
p value 0.028 0 .395
MGI= Modified gingival index
Table 3.4 Spearman rank correlation coefficients
between pocket depth and GCF volume and biochemical 
parameters (pg/30s) in GCF from 206 sites in 52 patients 
at the baseline examination. Probability levels (p) are 
shown.
Stromelysin TIMP
Vol r=0.331 (0.005) r=0.360 (p<0.001)
PD r=0.033 (0.667) r=0.034 (p=0.678)
and volume. The mean level of the SL was higher in males 
(p=0.464), and the anterior sites (p=0.872) (Table 3.5),
however, none of the differences were statistically
significant. The mean GCF SL was almost identical in
subjects older than 35 years (p=0.89).
The mean level of TIMP was higher in males compared to
females (p=0.1) and was higher in posterior sites than 
anterior sites (p=0.22). The subjects with less than 35 
years showed a higher level of TIMP compared to subjects 
with age higher than 35 years although these differences 
were not significant (Table 3.5).
The mean GCF volume was lower in smokers than non smokers, 
although it was not statistically significant (p=0.390). 
The mean GCF volume was almost identical in subjects with 
age more than 35 compared to subjects with age less than 
35. However, the mean GCF volume was higher in males than 
females (p=0.073) and was significantly higher in posterior 
compared to anterior sites (p=0.016).
In order to disclose the clinical characteristic of sites 
with different level of SL or TIMP, discriminate analysis 
was performed. The grouping criteria for SL was the 
detectability by the ELISA. For the TIMP, the test was 
considered positive when a site demonstrated TIMP< 370.4 
pg/30s. This threshold value represents the mean TIMP
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Table 3.5 The effects of smoking, sex, site and age on biochemical 
and clinical parameters in baseline, site was used as the unit of 
analysis (n=206), means & (SEM) are given. (Two sample t-test for log 
transform mean TIMP, PD, Vol and Mann-Whitney U test for SL, MGI, PI 
were used).
smoking sex age site
Sm non Sm female male <35 >35 Ant Post
n=115 n-91 n=128 n=78 n=28 n=l 78 n=145 n=61
SL 18.18 23 .17 17.55 25 . 04 14 . 72 21.28 22 .14 16.21
(1.98) (4.50) (1.88) (5.13) (1.55) (2.62) (3.17) (1.44)
p value 0.22 0.46 0.89 0.87
TIMP 315.5 267.5 253.5 361.3 313 291.4 247 . 8 404 . 7
(34.9) (36.2) (28.0) (47.3) (102) (24.5) (22.9) (63.5)
p value 0.34 0.10 0.26 0.22
GCF vol 0.442 0 .482 0 .427 0 . 514 0.431 0 .464 0.422 0.549
(0.03) (0.03) (0.03) (0.03) (0.05) (0.03) (0.03) (0.04)
p value 0.39 0.07 0.56 0.02
PD 5.53 5.53 5 . 52 5 . 54 5.30 5 . 57 5.62 5.32
(0.14) (0.12) (0.11) (0.16) (0.22) (0.10) (0.11) (0.16)
p value 0.98 0.94 0.26 0.12
GI 2.14 2.04 2.0 2 .23 2 .14 2.08 2 .15 1.95
(0.08) (0.07) (0.07) (0.08) (0.13) (0.66) (0.06) (0.10)
p value 0.35 0.06 0.76 0.14
PI 0.66 0.55 0.58 0.63 0.61 0.60 0.61 0.58
(0.08) (0.06) (0.06) (0.08) (0.12) (0.05) (0.06) (0.09)
p value 0.37 0.74 0.79 0.75
level in successfully treated sites at the reassessment 
visit.
Table 3.6, demonstrates the characteristic values for sites 
with detectable, and undetectable SL, as well as sites with 
high (>370.4 pg/30s) and low (<370.4 pg/30s) TIMP levels.
The analysis utilised a step-wise selection. To arrive at 
a good model, a variety of potentially useful variables are 
included in the data set. In the step-wise method the
first variable included in the analysis has the smallest 
Wilk's lambda provided that its p values is significant. 
Wilk's lambda is the ratio of the within group sum of
squares to total sum of squares. After the first variable 
is entered, the values of the criterion are re-evaluated 
for all variables not in the model, and the variable with 
the smallest Wilk's lambda value and a significant p value 
is entered next.
Table 3.7 shows the discriminate variables which were
eligible for entering into the model. These include GCF
volume and GCF TIMP level for discriminating between 
detectable and undetectable SL levels and GCF volume, GCF 
SL level and gender for discriminating between high and low 
TIMP levels. No other parameters had a small enough Wilk's 
lambda for entry.
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Table 3.6 The group mean of GCF TIMP, BOP, PI, MGI, Vol, 
PD, gender, Smoking, Site, and age on SL and TIMP. The 
grouping criteria for SL was the detectability of SL by 
the ELISA and TIMP<370.4=0 and TIMP>370.4=1.
SL TIMP
variables undetected detected <370.4
pg/30s
>370.4
pg/30s
Site (% Anterior) 71% 67% 75% 54%
BOP (% positive) 88% 93% 90% 89%
SUP (% positive) 15% 8% 10% 22%
Smoking (%smoker) 60% 46% 55% 59%
SEX (% female) 63% 59% 67% 46%
PD (mm) 5.57 5.42 5.5 5.6
vol (fil) 0.39 0 . 62 0 .40 0 . 67
PI 0.59 0.62 0 .60 0 . 59
MGI 2 .03 2 .21 2 . 09 2 .07
Age (year) 44 .48 43 . 92 39.41 44 .43
TIMP (pg/30s) 309.6 258 . 0 - -
SL (pg/30s) - - 21.14 17.76
Table 3.7 The Wilks' lambda and significance level 
the entry action of variables in the SL and TIMP.
Step Action Entered Wilk's 
Lambda
sig
SL
1 GCF Volume 0 . 91 <0.001
2 TIMP 0.87 <0.001
TIMP
1 GCF Volume 0 . 89 <0.001
2 SL 0.85 <0.001
3 Sex 0 . 86 <0.001
Table 3.8 and Table 3.9 show the number of cases classified 
correctly and incorrectly. The percent of ''grouped'' 
cases correctly classified was 69.42% for SL and was 70.39% 
for TIMP respectively.
3.2 The efficacy of adjunctive locally delivered
antibiotics on biochemical and clinical 
parameters
This study looked at changes in GCF SL and TIMP as a means 
of monitoring clinical changes in a 4 treatment study. The 
pocket depth and clinical indices are reported elsewhere 
and was not my personal work submitted by me as part of 
this MSc thesis. A summary of these results however is 
given. Comparison of changes in pocket depth, attachment 
level and GCF volume between treatment groups were 
performed with the ANCOVA test. Comparison of changes in 
these parameters before and after treatment was performed 
using the paired t-test. Comparison of MGI and PI before 
and after treatments was performed, using the Wilcoxon's 
test and comparison between treatment groups was carried 
out with the Kruskal-Wallis test. Changes in BOP were 
assessed using the chi-square test (% ) .
A total of 52 sites in 13 patients were selected in each 
treatment group. Six weeks after the last treatment visit
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Table 3.8 The number and percentage of cases classified
correctly and misclassified by the detectability of SL.
Actual group No. of 
Cases
Predicted group 
membership
0 1
Group 0 undetectable 145 104
(71.7%)
41
(28.3%)
Group 1 detectable 61 22
(36.1%)
39
(63.9%)
Total classified correctly = 69.42%
Sensitivity 39/61=64%
Specificity 104/145=71%
Table 3.9 The number and percentage of cases classified 
correctly and misclassified by the dichotomous grouping 
of TIMP.
Actual group No. of 
Cases
Predicted group 
membership
0 1
Group 0 TIMP<370.4 160 117 
(73.1%)
43
(26.9%)
Group 1 TIMP>370.4 76 18
(39.1%)
28
(60.9%)
Total classified correctly = 70.39%
Sensitivity 28/78=36%
Specificity 117/160=73%
all the patients were assessed at a reassessment visit. 
Overall, two treated sites had to be excluded from the 
study. The same clinical and biochemical sampling as the 
baseline visit were repeated at this visit. Wherever data 
was not normally distributed, it was logarithmically 
transformed in order to use parametric tests. Analysis was 
performed with regard to both the site and subject as the 
experimental unit. When the subject was considered as the 
unit of assessment, sites within each subject were averaged 
and one score produced per subject for each clinical and 
biochemical parameter. For sites giving values for SL and 
TIMP below the assay detection level, a value which was 
half the mean detection limit of the ELISA was used.
3.2.1 Change in the clinical finding after
adjunctive treatment with different 
locally delivered antibiotics or scaling 
and root planing alone
Pocket depth: At the time of initial subgingival therapy,
the average probing pocket depth was 5.5 mm, with no 
significant differences between groups (p=0.881). 
Significant testing revealed that a highly significant 
reduction in pocket depth occurred in all treatment groups 
(Table 3.10). Analysis of covariance (ANCOVA) showed 
significant difference between treatment groups when data
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was analysed on a subject basis (p=0.011). The results 
indicated that only tetracycline fibre treatment resulted 
in a significantly higher change in pocket depth than the 
scaling alone group (p=0.003) (Table 3.10).
Modified Gingival Index: Wilcoxon test showed that the
modified gingival index was significantly decreased after 
the treatments in all treatment groups. There was 
significant difference between treatment groups in terms of 
changes of modified gingival index (Kruskal-Wallis test, 
p<0.001). Mann-Whitney U test demonstrated that these 
differences were between i) tetracycline fibre plus scaling 
group and minocycline gel plus scaling group (p=0.002), ii) 
tetracycline fibre plus scaling group and metronidazole gel 
plus scaling group (p=0.007), and iii) tetracycline fibre 
plus scaling group and scaling alone group (p=0.001).
Bleeding on probing: 91.4 % of the sites bled on probing
at the pre-treatment visit. Significant testing revealed 
that all treatment modalities were effective in reducing 
the number of periodontal sites which bled on probing when 
compared to the initial visit (p<0.001).
Plaque Index: Due to the strict oral hygiene, maintenance
plaque index scores were low. The average plaque index did 
not significantly differ among the treatment groups at the 
baseline (p=0.575), and after the treatment (p=0.987).
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Table 3.10 Comparison of attachment level and pocket
depth and gingival volume between different treatments
using analysis of variance (ANCOVA), with subjects as
unit of analysis. Paired t-test was used to compare
before vs. after treatment.
n Mean dif SEM p value
Attachment level(mm)
Scaling & Tc fibre 13 0 .75 0 .12 <0 . 001
Scaling & Min gel 13 0 .40 0 .14 0 . 013
Scaling & Met gel 13 0.59 0 .14 0 . 001
S Sc R alone 13 0.26 0 .11 0.032
ANCOVA p value 0 . 048
Pocket depth (mm)
Scaling & Tc fibre 13 1.35 0 .17 <0 . 001
Scaling & Min gel 13 0.81 0 .13 <0.001
Scaling & Met gel 13 0 . 97 0.18 <0.001
S & R alone 13 0.60 0 .14 <0.001
ANCOVA p value 0 . Oil
GCF Volume (pi)
Scaling & Tc fibre 13 0.10 0.08 0.21
Scaling & Min gel 13 0 . 02 0 . 04 0 . 70
Scaling & Met gel 13 -0 . 05 0 . 05 0.33
S & R alone 13 0.06 0 . 05 0.20
ANCOVA p value 0.293
* after correction the significance threshold was <0.02
Tc fibre= Tetracycline fibre
Min gel= Minocycline gel
Met gel= Metronidazole gel
S & R= Scaling and Root planing
GCF volume: Although all the different treatments, except
the metronidazole gel treatment, were effective in reducing 
the volume of GCF in the treated sites, but none of the 
changes were significant. In addition, the change in the 
GCF volume was not statistically different between the 
different treatments (p=0.293) (Table 3.10).
Attachment level: Mean difference and SEM of attachment
level in each group are shown in Table 3.10. Paired t- 
tests showed no significant improvement at the reassessment 
in all treatment groups. Analysis of covariance failed to 
show significant differences between different treatment 
groups on both site and subject based analysis (p=0.048).
3.2.2 Change in the GCF stromelysin level after
adjunctive treatment with different 
locally delivered antibiotics or scaling 
and root planing alone
SL was detected in 40 (19.4%) sites at reassessment. The
enzyme level did not reach the detectable levels in any 
site in 28 (53.8%) subjects at the reassessment visits.
The mean GCF level of SL decreased in all antibiotic 
treated groups and was statistically significantly 
decreased in the tetracycline fibre plus scaling group
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Table 3.11 GCF SL Mean reduction after therapy in four
treatment groups, with site as the unit of analysis.
Stromelysin (pg/30s) TIMP (pg/30s)
n mean dif” P mean dif” P
S & Tc fibre 51 0.11(0.05) 0.020 -0.32 (0.07) 0.0001
S & Min gel 52 0.13(0.06) 0.023 -0.22 (0.08) 0.0051
S & Met gel 52 0.01 (0.30) 0.730 -0.38 (0.07) <0 . 001
S & R alone 51 -0.01 (0.06) 0.940 0.05(0.07) 0 .490
ANOVA p value 0.121 <0 . 001
* Paired t-test, baseline and post-therapy for each treatment
# Log transformed data
S & Tc fibre= Scaling & Tetracycline fibre 
S & Met gel= Scaling & Minocycline gel 
S & Min gel= Scaling & Metronidazole gel 
S & R= Scaling and Root planing
Table 3.12 GCF SL mean reduction after therapy in four
treatment groups, with subject as the unit of analysis.
Stromelysin (pg/30s) TIMP (pg/30s)
n mean dif* P mean dif* P
S & Tc fibre 13 0.16(0.82) 0 . 072 -0.33 (0.08) <0.001
S & Min gel 13 0.17(0.11) 0.150 -0.24 (0.10) 0 . 03
S & Met gel 13 0.02(0.05) 0 . 740 -0.38 (0 . 08) <0.001
S & R alone 13 -0.04 (0.07) 0 .560 0.07 (0.11) 0 .560
ANOVA p value 0 .174 0 . 010
* Paired t-test, baseline and post-therapy for each treatment
# Log transformed data
s & Tc fibre= Scaling & Tetracycline fibre 
S & Met gel= Scaling & Minocycline gel 
S & Min gel= Scaling & Metronidazole gel 
S & R= Scaling and Root planing
(p=0.020) and the minocycline gel plus scaling group 
(p=0.023) (Table 3.11). If the patient was considered as 
the unit of analysis, it was revealed that GCF mean levels 
of SL did not decrease significantly after treatment in any 
group but was almost significant in the tetracycline fibre 
plus scaling treatment group (p=0.072) (Table 3.12). The 
analysis of covariance (ANCOVA) on the baseline SL was used 
to reduce the error resulting from the variation in the 
baseline, i.e. to adjust out, mathematically, for the small 
differences at the baseline that might exist. When data 
was analysed both on the site and subject basis, the level 
of SL at baseline had significant effects on the response 
to treatment (p<0.001), and this effect was positive i.e. 
the higher the baseline SL, the higher the reduction of SL. 
After the mean differences were adjusted for baseline 
values, the mean reduction in both the tetracycline fibre 
plus scaling and minocycline gel plus scaling groups were 
still considerably higher than those of the metronidazole 
gel plus scaling and scaling alone groups (Table 3.13). 
The treatment also had a significant effect on the
reduction of SL (p=0.001). Follow-up analysis showed
significant differences between i) tetracycline fibre plus 
scaling and the scaling alone group (p=0.004), ii)
minocycline gel plus scaling and the scaling alone group 
(p=0.002) (Table 3.13). However, if the patient was 
considered as the unit of analysis, there was no
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Table 3.13 Statistical analysis of changes of GCF level
of Stromelysin between test groups (n=206), with site as
the unit of analysis.
A. Mean (SEM) for 206 sites
Test Group Baseline SL Mean dif# SL
Scaling & TC 1.17 (0.04) 0.11 (0.05)
fibre (n=51)
Scaling & Min 1.17 (0.05) 0.13 (0.06)
gel (n=52)
Scaling & Met 1. 08 (0.03) 0.01 (0.30)
gel (n=52)
Scaling alone 1. 21 (0.04) -0.01 (0.06)
(n=51)
B. Analysis of covariance
Source DF ss MS F P
Baseline SL 1 14 .59 14.59 291.03 <0.001
Treatments 3 0 . 897 0.30 5.97 0 . 001
Error 47 10 . 07 0 . 05
Total 51 25.38
C. Significance
Scaling & Min Scaling & Met Scaling
gel gel alone
Scaling & TC 0.658 0.509 0.004
fibre
Scaling & Min 0.377 0.002
gel
Scaling & Met 0 . 035
gel
TC fibre= Tetracycline fibre DF= Degree of freedom
Min gel= Minocycline gel SS= sum of square
Met gel= Metronidazole gel MS= Mean square
* Adjusted for baseline level
** After correction the significant threshold was <0.020
# Log transformed data
Table 3.14 Statistical analysis of changes of GCF level
of stromelysin between test groups (n=52), with subject
as the unit of analysis.
A. Mean (SEM) for 52 patients
Test Group Baseline SL Mean dif# SL
Scaling & TC 1.24 (0.07) 0.16 (0.82)
fibre (n=13)
Scaling & Min 1.25 (0.09) 0.17 (0.11)
gel (n=13)
Scaling & Met 1.11 (0.04) 0.07 (0.05)
gel (n=13)
Scaling alone 1.26 (0.07) -0.04 (0.07)
(n=13)
B. Analysis of covariance
Source DF SS MS F P
Baseline SL 1 2 . 04 2.04 48.26 <0.001
Treatments 3 0.44 0.15 3.47 0 . 023
Error 47 1.99 0.04
Total 51 4.46
C. Significance
Scaling & Min Scaling & Met Scaling
gel gel alone
Scaling & TC 0 . 903 0.625 0 . 023
fibre
Scaling & Min 0 . 915 0 . 044
gel
Scaling & Met 0 .227
gel
TC fibre= Tetracycline fibre DF= Degree of freedom
Min gel= Minocycline gel SS= sum of square
Met gel= Metronidazole gel MS= Mean square
* Adjusted for baseline level
** After correction the significant threshold was <0.020
# Log transformed data
significant difference between treatment groups (Table 
3.14) .
3.2.3 Change in the GCF tissue inhibitor
metalloproteinase level (TIMP) after 
adjunctive treatment with different locally 
delivered antibiotics or scaling and root 
planing alone
TIMP was detected in 205 (99.5%) sites. Paired sample t-
test demonstrated that the level of GCF TIMP significantly 
increased in all antibiotic treatment groups, whereas it 
decreased in scaling groups although not significantly 
(p=0.49). One-way analysis of variance demonstrated a 
significant difference among the groups for changes in the 
GCF TIMP levels (p<0.001) (Table 3.11). When Tukey's test 
was employed to determine direction and location of 
difference, it showed that all antibiotic therapy groups 
were significantly different from the scaling alone group. 
However, no significant difference was found between 
antibiotic therapy groups (Table 3.11). The results of the 
subject basis analysis was similar to those of site basis 
analysis (Table 3.12) . When data was analysed on the site 
basis, ANCOVA showed that the level of TIMP at the baseline 
had a significant effect on the response to treatment 
(p=0.007), i.e. regardless of treatment type, the higher
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Table 3.15 Statistical analysis of changes of GCF level
of TIMP between test groups (n=206) , with site as the
unit of analysis.
A. Mean (SEM) for 206 sites
Test Group Baseline TIMP Mean dif# TIMP
Scaling & TC 2 .12 (0.06) -0.32
fibre (n=51)
Scaling & Min 2.30 (0.06) -0.22
gel (n=52)
Scaling & Met 2 .19 (0.06) -0.38
gel (n=52)
Scaling alone 2.39 (0.06) 0 . 05
(n=51)
B. Analysis of covariance
Source DF ss MS F P
Baseline 1 20.53 20.53 119.25 <0.001
TIMP
Treatments 3 2 .13 0.71 4.13 0.007
Error 201 34 .61 0 .17
Total 205 60.73
C. Significance
Scaling & Min Scaling & Met Scaling
gel gel alone
Scaling & TC 0.503 0.170 0.036
fibre
Scaling & Min 0 .400 0.018
gel
Scaling & Met 0 . 001
gel
TC fibre= Tetracycline fibre DF= Degree of freedom
Min gel= Minocycline gel SS= Sum of square
Met gel= Metronidazole gel MS= Mean square
* Adjusted for baseline level
** After correction the significant threshold was <0.020
# Log transformed data
Table 3.16 Statistical analysis of changes of GCF level
of TIMP between test groups (n=52), with Subjects as the
unit of analysis.
A. Mean (SEM) for 52 patients
Test Group Baseline TIMP Mean dif# TIMP
Scaling & TC 2.20 (0.09) -0.33 (0.08
fibre (n=13)
Scaling & Min 2.38 (0.09) -0.24 (0.10)
gel(n=13)
Scaling & Met 2.30 (0.09) -0.38 (0.08)
gel (n=13)
Scaling alone 2.53 (0.08) 0.07 (0.11)
(n=13)
B. Analysis of covariance
Source DF ss MS F P
Baseline 1 2 .21 2.21 34.03 <0.001
TIMP
Treatments 3 0.43 0.14 2.23 0 . 097
Error 47 3 . 05 0 . 06
Total 51 6.65
TC fibre= Tetracycline fibre DF= Degree of freedom
Min gel= Minocycline gel SS= Sum of square
Met gel= Metronidazole gel MS= Mean square
* Adjusted for baseline level
** After correction the significant threshold was <0.020
# Log transformed data
the TIMP level at the baseline, the higher the change of 
TIMP level after treatment. Results revealed a significant 
difference between the minocycline gel plus scaling and the 
scaling alone group (p=0.018), and also between 
metronidazole gel plus scaling and scaling alone group 
(p=0.001) (Table 3.15). However, if the patient was 
considered as the unit of analysis, there was no 
significant difference between the different treatments 
(p=0.097) (Table 3.16).
3.2.4 The effects of smoking, sex, site, and age
on changes of GCF SL, TIMP, and volume
The effects of smoking status, location of site, sex, and 
age on changes of GCF SL are presented in Table 3.17. 
None of these factors had any significant effect on SL 
level. Nevertheless, the change in SL level was lower in 
smokers, females, subjects less than 35 years and posterior 
sites, compared to non-smokers (p=0.20), males (p=0.12), 
subjects over 35 years (p=0.79) and anterior sites (p=0.65) 
respectively.
The effects of smoking, sex, site, and age on the changes 
of GCF TIMP were demonstrated to be insignificant. The 
change in GCF TIMP was lower in non-smokers, females, 
subjects over 35 years and anterior sites compared to
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Table 3.17 The effects of smoking, sex, site and age on 
changes of GCF SL, TIMP and volume after treatment. 
Sites was used as the unit of analysis (n=206) . Two 
sample t test was utilised. Means & (SEM) are given.
smoking sex age site
Sm non sm F M <35 >35 Ant Post
n=115 n=91 n=128 n=7 8 n=28 n=17 8 n=145 n=61
ASL* 0 . 03 0.1 0.03 0.11 0.05 0.06 0.08 0.06
(0.03) (0.04) (0.05) (0.04) (0.04) (0.03) (0.04) (0.03)
P 0.20 0 .12 0.79 0.65
ATIMP* -0.28 -0.14 -0.21 -0.24 -0.27 -0.21
(N<NO1«-l(NO1
(0.05) (0.06) (0.05) (0.06) (0.01) (0.04) (0.04) (0.07)
P 0 . 08 0.69 0. 59 0. 97
AGCF 0 . 01 0. 04 0.01 0.06 -0 . 02 0.03 0.02 0.03
vol (0.03) (0.04) (0.03) (0.04) (0.08) (0.03) (0.03) (0.05)
P 0. 560 0.340 0 .490 0.910
# Log transformed data
Table 3.18 Correlation of PD and GCF Vol with SL and 
TIMP at the reassessment visit, with the site as the unit
of analysis (n=206).
Stromelysin(pg/30s) TIMP (pg/30/s)
Vol(nL) r=0.108 (0.049) 0.389 (p<0.001)
PD (mm) r=0.188 (p=0.058) 0.194 (p=0.068)
PD= Pocket depth 
Vol= Volume
smokers subjects (p=0.08); males (p=0.69); subjects less 35 
years (p=0.59) and posterior sites (p=0.97) respectively 
(Table 3.17). These changes were almost completely 
opposite to those reported for SL alone.
The changes of mean GCF volume was lower in smokers, 
females and anterior sites compared to non-smokers 
(p=0.56); male (p=0.34) and posterior sites (p=0.91) 
respectively. The mean GCF volume decreased slightly in 
subjects over 35 years but it increased slightly in 
subjects less than 35 (p=0.49) (Table 3.17).
General linear model procedures (GLM) was used to take into 
account the effect of factors, such as smoking, sex, and 
site, while examining the effect of treatment on the 
changes of SL or TIMP. The results showed none of the 
individual effects were significant (p value for 
smoking=0.101, sex=0.136, sites=0.686, age=0.416).
3.2.5 Correlation between pocket depth, GCF volume
and GCF levels of SL and its inhibitor at 
reassessment
The mean levels of SL and TIMP showed positive associations 
with the mean GCF volume and pocket depth. However, the 
correlations were low (Table 3.18).
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3.2.6 Prediction of response to treatment
according to the baseline level of 
stromelysin and tissue inhibitor of 
metalloproteinases
In order to determine the success of treatment, all sites 
were examined for bleeding on probing and pocket depth at 
the reassessment visit. Treatments were considered
successful, when the sites did not show bleeding on probing 
and had a pocket depth of equal or less than 3.5 mm. 
Overall twenty six (12.6%) sites were found which showed 
both criteria for treatment success at the reassessment 
examination, whereas one hundred and seventeen (56.8%) 
sites were detected which still had bleeding on probing and 
pocket depth over 3.5 mm. The former category was assigned 
as the 'best responding sites' (BRS) and the latter as the 
'worst responding sites' (WRS). The baseline levels of 
stromelysin, and TIMP in the best responding sites (BRS) 
(n=26) and the worst responding sites (WRS) (n=117) were 
compared in order to investigate their ability to predict 
treatment outcome. The Mann-Whitney U test was made to 
compare the baseline GCF SL between the WRS and BRS, and 
the two sample t-test was used to compare the baseline GCF 
TIMP between the WRS and BRS. The changes in GCF TIMP and 
SL between the WRS and the BRS was subjected to the two 
sample t-test.
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3.2.6.1 Prediction of response to treatment
according to the baseline levels of 
stromelysin and comparison of BRS and WRS 
in their change of stromelysin levels.
Table 3.19 presents the level of GCF SL, and TIMP as well 
as volume at the BRS and WRS at the baseline. The mean GCF 
levels of SL at the baseline failed to differentiate 
significantly between sites without BOP and PD<3.5 mm (BRS) 
and those with BOP and pocket depth of more than 3.5 mm 
(WRS) (Mann-Whitney U test, p=0.459). However, the results 
showed that the mean level of SL in the BRS was lower than 
the WRS at the baseline. There was also no significant 
difference between the WRS and the BRS in the level of SL 
change (p=0.16). However, SL decreased three times more in 
the BRS than the WRS but due to the presence of large 
variability no significant difference was demonstrated. 
The comparison of the WRS and the BRS, broken down by their 
treatments, indicated that in all treatment groups the 
post-treatment reduction of SL was higher in the BRS than 
the WRS, although it was not statistically significant 
(Table 3.20) .
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Table 3.19 Comparison of GCF stromelysin (SL) , GCF 
TIMP, volume (Vol) at the baseline examination between 
BRS and WRS, using Mann-Whitney U test for GCF SL, Two 
sample t-test for GCF TIMP and volume. Mean & (SEM) are 
given.
BRS (n=26) WRS (n=117) p value
SL 18.82 (2.66) 20.44 (2.52) 0 .459
TIMP 263.2 (51.3) 317.9 (35.1) 0 .410
Vol 0.441 (0.056) 0.496 (0.033) 0.706
Table 3.20 Comparison of changes of GCF 
(SL) , GCF TIMP, volume (Vol) between BRS and 
Two sample t-test, Probability value and log10 
mean & (SEM) are given .
stromelysin 
WRS, using 
transformed
BRS (n=26) WRS (n-117) p value
ASL 0.14 (0.06) 0.04 (0.03) 0.16
ATIMP -0.22 (0.16) -0.21 (0.05) 0.99
A Vo I 0.13 (0.07) -0.01 (0.35) 0.09
3.2.6.2 Prediction of response to treatment according
to the baseline level of TIMP and comparison 
of BRS and WRS in their change of TIMP 
levels.
The two sample t-test did not show any significant 
difference between the mean baseline TIMP level in the BRS 
and the WRS (two sample t-test, p=0.410); Although the GCF 
level of TIMP was demonstrated to be lower in the BRS than 
the WRS at baseline (Table 3.19). Statistical analysis of 
changes in GCF TIMP failed to show any significant 
difference between BRS and WRS overall (p=0.99) (Table 
3.20). Comparison between changes of TIMP in different 
groups of treatment revealed that in all the treatment 
groups, the TIMP changes were higher in BRS compared to WRS 
(Table 3.21), although that change was not significant.
3.2.7 Prediction of response to treatment (changes
in the attachment levels) according to the 
baseline GCF levels of stromelysin and TIMP
All the sites were broken down according to their change in 
attachment levels; a) sites with attachment gain>l mm, b)
sites with attachment gain between zero and 1 mm, and c)
sites with attachment loss. The change in the SL and TIMP
level were compared in the sites with attachment gain>l mm
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Table 3.21 Comparison of changes of GCF stromelysin (SL) 
and GCF TIMP between BRS and WRS in four different 
treatments, using Two sample t-test. Log transformed 
mean difference & (SEM) are given.
n . BRS BRS n . WRS WRS p value
Tetracycline 9 21
Fibre
AStromelysin 0 .14 0.08 0 . 08
(0.07) (0.08)
AT IMP -0.38 0 .32 0.86
(0.29) (0.11)
Minocycline Gel 5 30
AStromelysin 0.29 0 .11 0 .24
(0.13) (0.06)
AT IMP -0.27 -0.26 0 . 98
(0.32) (0.08)
Metronidazole 6 31
Gel
AStromelysin 0.06 0.01 0 .44
(0.06) (0.04)
AT IMP -0.43 -0.38 0.90
(0.36) (0.08)
Scaling & Root 6 35
planing
AStromelysin 0 . 08 0.01 0 . 74
(0.19) (0.08)
AT IMP 0.28 0.04 0 .21
(0.15) (0.09)
and the sites with attachment loss. 43 sites (20.87%) had 
attachment gain from the baseline level, whereas 53 sites 
(25.73%) showed attachment loss from the baseline.
Mann-Whitney U test failed to distinguish between the mean 
GCF SL of the attachment gaining sites (AGS) and the 
attachment losing sites (ALS) at the baseline (Mann-Whitney 
U test, p=0.84) (Table 3.22) . There was no significant 
difference between AGS and ALS sites at the reassessment 
visit, when they were compared for their mean baseline 
levels of TIMP (two sample t-test, p=0.63) (Table 3.23). 
Therefore, the TIMP and SL mean baseline were not able to 
predict the response to the treatment as defined by 
attachment level changes.
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Table 3.22 Comparison of GCF stromelysin (SL) , GCF 
TIMP, volume (Vol) at the baseline examination between 
sites with attachment gain (AAL>1) and sites with 
attachment loss (AAlcO), using Mann-Whitney U test for 
GCF SL, two sample t-test for GCF TIMP, and volume.
AGS (n=43) ALS (n=53) p value
SL 17.82 (2.05) 28.06 (7.87) 0.84
TIMP 247.3 (55.9) 235.5 (37.5) 0 . 63
Vol 0.442 (0.05) 0.445 (0.05) 0.91
AGS= Attachment gain sites 
ALS= Attachment loss sites
CHAPTER 4 
DISCUSSION
4.1 Clinical design
The study was designed as a parallel study to avoid cross 
over effects between different antibiotic treatments. In 
order to avoid bias in judgement and provide a basis for 
the standard methods of statistical analysis, patients were 
randomly allocated to four different groups, thus each 
patient had a 25% chance of being assigned to treatment. 
The subjects in four treatment groups were balanced on the 
basis of factors suspected to have an influence on the 
outcome such as smoking and age.
The clinical design of this experiment allowed evaluation 
of the effect of three different locally delivered 
antibiotics on the level of SL and TIMP GCF.
4.2 The choice of biochemical parameters
The reason for selecting fibroblast SL in this study was 
that SL has been shown to be a marker of stromal cell 
involvement in the process of tissue degradation (Birkedal-
Hansen et al., 1993) and it has also been suggested that SL
may play a role in chronic inflammatory periodontitis 
(Ingman et al. , 1994a,b) . The fibroblast type of SL is
chosen because fibroblast-type collagenases have been shown 
to be constutively synthetised and secreted by fibroblasts,
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whereas the human neutrophil collagenase is stored in intra 
cellular specific granules, having been synthesised during 
neutrophil maturation in bone marrow. Thus, the levels of 
this MMP released by mature circulating neutrophils are 
regulated by factors that affect degranulation rather than 
biosynthesis of collagenase (Birkedal-Hansen, 1988). For 
this reason fibroblast stromelysin (MMP-3) was used in the 
study. Meanwhile, since it has been shown that systemic 
tetracycline administration does not inhibit well 
fibroblast derived MMPs (Golub et al., 1991), it was
decided to utilise local delivery systems which provide 
high concentration of tetracycline that can inhibit all 
MMPs such as PMN and fibroblast origin.
4.3 Methodological considerations
4.3.1 Quantification of gingival crevicular fluid
stromelysin and tissue inhibitor of 
metalloproteinases
The enzyme linked immunosorbent assay (ELISA) used in this 
study was validated and proven suitable for the 
quantification of MMPs and TIMP in GCF and has several 
advantages over other methods. First, the ELISA assay 
system does not require radioactive materials which are 
expensive and hazardous. Second, the test is convenient,
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simple and can be carried out within a few hours. Third, 
it is suitable for dealing rapidly with a large number of 
samples.
The ELISA methodology has important technical aspects so 
that careful attention to experimental protocol is
essential to ensure accurate and reproducible results.
However, this method has some inherent problems such as,
high background, edge effects and the hook effect, which 
may introduce erroneous results or make their 
interpretation difficult. Increasing the number of wash 
steps and also using a non specific protein i.e. bovine 
serum albumin (BSA) to bind unreacted sites in solid phase 
can prevent the high background in the ELISA technique. In 
these experiments the optical density (OD) for control 
wells were much lower than those obtained for both samples 
and standards, therefore this was not such a problem here. 
The use of inside wells for running samples and controls 
can prevent the edge effect of the ELISA technique as it 
has been reported that the outside wells of a plate may 
absorb more protein than the inside wells, resulting in 
assay bias (Tijssen, 1985; Carpenter, 1992) . Low affinity 
antibody, inadequate washing and suboptimal concentrations 
of labelled antibody have been suggested as possible causes 
of the hook effect. This is an unexpected fall in the
amount of substance at the end of the dose response curve, 
resulting in a gross underestimation of the substance
100
(Carpenter, 1992) . However, in the present experiments 
such an effect was not demonstrated.
4.4 Gingival crevicular fluid
In this study GCF data were reported as absolute amounts of 
GCF constituent per 3 0s sample, and does not include the 
volume of GCF in its calculation. This method may be 
subject to less variance and is probably less sensitive to 
alterations caused by evaporation or contamination of the 
sample which would appear to be unpredictable, irrespective 
of the sampling technique used. The rational for
expressing results of GCF constituents as absolute amount 
(pg/30s) has been discussed extensively (Lamster et al., 
1986, Lamster et al., 1988 a,b).
In the present study paper strips placed just into the 
crevice for 30 seconds were utilised for GCF collection to 
minimise irritation and microleakage of the subepithelial 
microvasculature. Such a non-invasive method can provide a 
sample which is truly from a pool of biochemical compounds 
in the GCF, and has not been influenced by the influx of 
the enzymes and biochemical markers from the serum as a 
result of trauma to blood vessels during the sampling 
technique.
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4.5 Statistical analysis
Using the ANOVA it is possible to draw conclusions about 
only one parameter which is a variable of interest to the 
researcher. In this situation, to obtain a valid
inference, all other parameters should ideally be similar 
across the test groups. Otherwise the differences in some 
parameters could have important influences on the outcome 
variable. In the biological studies it is practically 
impossible to obtain samples of subjects which differ from 
each other only in one parameter. Randomisation is a 
suitable compromise by evenly distributing the factors with 
likely influence among the test groups. Nevertheless 
serious imbalance in such factors is not unlikely and can 
damage severely the validity of the statistical analysis. 
Analysis of covariance was used in the present study with 
the change in biochemical parameters as the main effect and 
the baseline values as continues covariated. Inspection of 
data indicated a large variability among the baseline 
values. When uncorrected changes in SL and TIMP were 
compared between treatment groups using ANOVA no 
statistically significant difference was found. However, 
covariance values of changes in SL and TIMP adjusted were 
proved to be significant among treatment groups when ANCOVA 
was used for the site base data. This indicates that 
ANCOVA is a more powerful statistical method than ANOVA.
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Nowadays, there is evidence that host factors are crucial 
in periodontal diseases. The conclusion of longitudinal 
studies is that; a) the progression of destructive 
periodontitis is subject-related; b) in the absence of 
treatment, inflammatory periodontal lesions will not 
necessarily progress; and c) comparatively few individuals 
in a population show advanced periodontal breakdown 
(Goodson et al., 1982; Albandar et al., 1986). Therefore, 
the current view is that periodontal disease is subject 
related. However, it should be born in mind that host 
factors influence all sites within the same mouth but site 
responsiveness to the treatments differ from site to site 
which may be due to the different composition of 
microbiota, or the morphology of the lesion. Furthermore, 
variation exists between the activity of diseased sites, 
thus if a site is considered as the unit of observation and 
the subject is considered as the unit of analysis, the 
question arises as to the effect upon the latter of the 
vast majority of inactive sites.
This is important in analysis of biochemical parameters 
which have shown high variations between the sites. In 
addition, in our study the sites which showed attachment 
loss occurred in some sites in the different individuals. 
With regard to these considerations, data in this study 
were analysed with site and subject as the unit of analysis
103
in order to consider both site specificity and subject 
specificity.
4.6 GCF metalloproteinases after locally
delivered antibiotic therapy
4.6.1 A cross sectional analysis of the association
between GCF SL and TIMP levels and clinical 
parameter at the baseline
The large fluctuation in amount of GCF SL and TIMP within 
patient and sites may be due to variability in the 
pathogenicity of the microbiota at different sites. This 
may result in variation in local host response and thus, 
variation in the levels of biochemical mediators harvested 
from GCF.
Yanagimura et al. (1989) demonstrated that the collagenase 
activities in GCF from subjects receiving maintenance care 
was significantly lower than that observed in the non­
therapy subjects. Haerian et al. (1994) found that the
level of SL and TIMP were lower in maintenance patients. 
With regard to these studies, one of the reasons why GCF SL 
was detected in only 29.6% of sites, was that study 
patients in this investigation had already received 
periodontal treatment. Bunning et al. (1984) showed that
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the physiologic inhibitors a2-microglobulin and tissue 
inhibitor of metalloproteinases (TIMPs) inhibit the 
fibroblast collagenase more efficiently than neutrophil 
collagenase. It is highly likely that active SL reaching 
the crevice would readily bind to inhibitors and causes SL 
in GCF not to be detected by this technique.
TIMP was detected in 99% of sites, which could be related 
to the presence of other MMPs in the inflamed gingiva which 
together increase tissue destruction and stimulates TIMP 
production (Nomura, Takahashi & Hara, 1993).
As bleeding on probing and suppuration are regarded as 
signs of periodontal disease (Haffajee, Socransky & 
Goodson, 1983a; Badersten, Neileus & Egelberg, 1990), the 
level of SL and TIMP were compared in different groups of 
sites. Our results showed that the levels of SL in the GCF 
have a relation with gingival inflammation scores, and also 
the levels of SL were higher in sites with bleeding on 
probing than in sites with did not bleed on probing. 
However, in suppurative sites the level of SL was lower 
than non suppurative sites. These results provide some 
insight into the level of SL in GCF and is probably simply 
a measure of the degree of inflammation. It can possibly 
also be considered as a measure of net collagen breakdown 
or tissue destruction.
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Since the GCF SL showed a significant difference between 
gingival inflammation scores, and also a high level of SL 
was present in sites with bleeding on probing than sites 
with no bleeding on probing, SL may also be considered as a 
marker of inflammation.
The level of GCF TIMP increased after treatment; it can be 
speculated that the level of TIMP in GCF can be considered 
as a measure of health. This is consistent with those 
reported by Haerian et al. (1995b).
4.6.2 Comparison between GCF level of SL, TIMP and
volume considering smoking, gender, age, and 
anterior vs. posterior sites
Recent data from several sources indicate that demographic 
variables within a study population can influence factors 
associated with periodontal disease and disease 
characteristics. Previous studies have also shown that 
demographic factors also influence the periodontal 
microflora, which might be expected in as much as immune 
and inflammatory responses commonly are considered to be 
crucial in the containment of periodontal bacterial flora.
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The objective of the assessment of data in terms of 
smoking, gender, age, and position of sites was to detect 
whether these variables had any effect on GCF SL and TIMP.
Previous studies have shown that the association between 
smoking and increased prevalence and incidence rates of 
periodontal disease have suggested that smoking has a 
strong association with severity of periodontal disease. 
This could be explained by a number of biologic phenomena. 
Nicotine and its by-products have a vasoconstrictive 
effect, on peripheral gingival blood vessels (Baab, & 
Oberg, 1987). In addition, smoking may reduce the 
functional activity of leukocytes and macrophages in saliva 
and crevicular fluid, and decrease chemotaxis and 
phagocytosis of blood and tissue polymorphonuclear (PMN) 
leukocytes, thereby depressing phagocyte-mediated 
protective responses to periodontal pathogens (Palmer, 
1988). Grossi et al. (1994) reported less healing after
mechanical treatment in smokers compared to non-smokers and 
showed this decreased clinical response was associated with 
less reduction of subgingival microorganisms. Data from 
changes of SL are consistent with the findings of Grossi et 
al. (1994) who showed higher clinical changes in non-
smokers. Our results also confirmed those of Baab & Oberg 
(1987) who showed the GCF volume is lower in smokers 
compared to non-smokers.
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Our results demonstrated that the mean level of SL was 
lower in smokers than non-smokers whereas the mean levels 
of TIMP was higher in smokers compared to non-smokers. The 
mechanisms that lead to differences in the SL between 
smoker and non-smokers are unclear, but some hypotheses 
indicate that it may be due to dysfunction of 
polymorphonuclear (PMN) leukocytes which indirectly 
influence production of SL from fibroblasts. With regard 
to the results of Ding et al. (1994) who demonstrated low
activities of MMPs GCF in periodontitis smokers compared to 
healthy smokers, the level of free TIMP in smokers is 
expected to be higher compared to non-smokers.
Our observations showed the level of SL was higher in 
subjects more than 3 5 years of age compared to subjects 
less than 35. However, the level of TIMP was higher in 
subjects less than 35 years compared to subjects more than 
35 years. The changes were higher in subjects over 35 
years whereas changes of TIMP were higher in subjects less 
than 35 years. Epidemiological evidence suggests that 
evidence of periodontal breakdown is increased with age. 
Grossi et al. (1994) demonstrated the prevalence of target 
periodontal pathogens based on species were different in 
different ages. This study also showed subjects in younger 
age categories were at lower risk for clinical attachment 
loss and also the risk of attachment loss were greater in 
males compared to females. Aass, Tollefsen & Gjermo (1994)
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showed that the frequency of subjects with radiographic 
alveolar bone loss increased significantly with age. Ismail 
et al. (1990) showed that age is a risk factor or predictor
of loss of periodontal attachment. Papapanou et al. (1990)
suggested that loss of periodontal attachment is more 
related to baseline loss of periodontal attachment than to 
age. There is no evidence in these studies to show whether 
these changes are due to increased experience of 
periodontal disease or are part of the ageing process or 
both.
Grossi et al. (1994) demonstrated that the prevalence of
the target periodontal pathogens were greater in males than 
females. Our results showed that the level of SL and TIMP 
were higher in males than females and also changes of these 
enzymes were higher in males than females. There is no 
evidence to show any sex differences between MMPs GCF. In 
addition the higher level of GCF volume in males than 
females can be due to higher plaque index scores and 
gingival inflammation scores in males compared to females.
Previous studies have shown that molar teeth with furcation 
involvement, responded less well to treatment compared to 
premolars and anterior teeth (Nordland et al., 1987, Loos 
et al., 1989). However, it could be due to difficulty in 
removal of subgingival plaque and calculus in molar 
furcation areas and poor accessibility of instruments to
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furcation areas. Our results showed that changes of SL 
were higher in anterior sites, however it cannot be 
established that site position alone is a marker of 
response to treatment.
The efforts were made to disclose the relationship of these 
enzymes to demographic parameters which are supposed to 
have an effect on the prevalence and response to treatment 
of periodontal disease.
Since the previous studies showed the level of SL activity 
and also the amount of this enzyme may serve as an 
indicator of patients with periodontal disease, 
discriminate analysis was performed to discriminate the 
sites at which SL were detected, and also sites with high 
and low levels of TIMP, by clinical and demographic 
parameters. Among 11 variables only the GCF volume and 
TIMP levels were able to differentiate between sites with 
and sites without detectable SL. The GCF volume and SL
level and sex could discriminate sites with high level of
TIMP from sites with low level of TIMP. This indicates
that, it is difficult for the clinical parameters to
discriminate the different levels of biochemical parameters 
in GCF.
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4.6.3 Effects of antimicrobial treatment on level
of GCF SL and TIMP
Antibiotics are often advocated as useful adjuncts in 
periodontal therapy based on their effectiveness against 
periodontopathogens (Lindhe et al. , 1983; Gusberti, Syed & 
Lang, 1988; McCulloch et al. 1990; Kulkarini et al., 1991).
Golub et al. (1987) demonstrated that tetracyclines inhibit
MMPs activity by a mechanism independent of their 
antimicrobial activity. It was shown that the systemically 
administrated tetracycline could inhibit collagenases 
derived from inflammatory sources but inhibition of 
fibroblast collagenase activity needed higher 
concentrations than could be achieved by this method of 
delivery (Golub et al., 1985a, 1987b, 1990, 1991, 1992; Lee 
et al., 1991). Therefore, it is supposed that locally 
delivered tetracyclines can inhibit both collagenase 
origins. Metronidazole appears to reduce the prevalence of 
Porphyromanas gingivalis and spirochetes at active sites in 
recurrent periodontitis subjects (Loesche et al., 1984). 
In addition, the results of Teng et al. (1992) suggest that 
metronidazole treatment can cause the reduction of both 
active and latent forms of gelatinase. The reduction of 
gelatinase activity is best explained by the antimicrobial 
effect of metronidazole which appears to blunt destructive 
host immune and inflammatory responses.
Ill
Our observation that the mean level of SL decreased after 
antibiotic treatment could be explained by the fact that 
local delivery antibiotics plus scaling and root planing 
may change the microbial flora. This may indirectly or 
directly cause a larger decrease of MMPs than scaling and 
root planing alone. It also confirmed that the use of 
antimicrobial agents as a supplementary treatment increases 
this effect. However, the greatest decrease was observed 
in the sites treated by tetracycline or minocycline 
delivery systems. Previous studies have also shown that 
tetracyclines, in addition to decreasing the level of 
microbial periodontal pathogenic bacteria, resulting in a 
decrease of MMP activity in the gingiva, could decrease the 
synthesis of pro-MMPs (Rifkin, Vernillo & Golub, 1993; 
Uitto et al., 1994) and also protect the endogenous MMP
inhibitors (TIMP-1) (Sorsa et al., 1993) and other
proteinase inhibitors (al-antitrypsin) (Sorsa et al., 1993) 
from degradation and inactivation by direct and indirect 
mechanisms. However, it can not be established from this 
study whether the effect of the tetracyclines on the level 
of SL is direct, or indirect through the reduction in 
microbial challenge. This reduction could result in
reduction in the microbial proteases and inflammatory
mediators such as cytokines, both of which could reduce the 
production of human MMP. However, the results of the 
present study demonstrate the effectiveness of antibiotic 
therapy in reducing crevicular fluid SL level, but it
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cannot be established from this study whether the effect of 
the antibiotic on the level of SL is direct, or indirect 
through the reduction in inflammation. This reduction in 
inflammation could be a consequence of a reduction in 
antibiotic-sensitive bacteria or the antibiotics could also 
have a direct, or indirect effect on cells that produce SL. 
In addition, the use of ELISA methodology, for the 
quantification of SL in GCF could be criticised for its 
inability to distinguish between active and latent forms of 
SL because it cannot be proved from this study whether the 
effect of the tetracyclines on the level of SL is direct, 
or indirect through the reduction in active or latent SL.
After treatment, the level of TIMP increased. This might 
be due to the tendency of free TIMP to bind to active 
collagenase, SL, and gelatinase (Cawston et al., 1983;
Murphy et al., 1989; Howard et al., 1991). The elevation 
of GCF TIMP was more elevated in the metronidazole group 
than in the other groups. This indicates that the 
regulation of TIMP is not solely dependent on the MMPs. 
The level of GCF TIMP was significantly elevated in the 
patients who were treated with antimicrobial agents. 
However, it did not significantly change in the scaling 
group. It could be speculated, that the extent of healing 
in the group of patients who received local delivery 
antibiotics was greater than the group who only received
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scaling. It has been suggested that MMP and TIMP 
expression can be independently regulated (Overall, 1994).
4.6.4 Correlation between clinical parameters and
gingival crevicular fluid biochemical 
components
In assessing the potential importance of the associations 
of SL and clinical parameters Spearman rank correlation 
coefficients was performed. It was found that the 
correlation coefficients between pocket depth and 
biochemical parameters were weak at baseline, whereas the 
GCF volume correlation with biochemical parameters were 
rather strong. At the reassessment visit, the correlations 
of biochemical parameters and pocket depth and GCF volume 
were also weak, whereas the correlations in both baseline 
and reassessment visits were positive. The positive 
correlation between GCF volume and TIMP was unexpectedly 
positive which can be due to the local production of TIMP. 
Since the MGI and PI were categorical data the correlation 
coefficient were not performed.
The large inter site variation in the levels of SL and TIMP 
observed in this study may, in part, be responsible for the 
lack of correlation between proteins and clinical 
parameters. Further studies are required to determine
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whether variation in the amount of SL among sites is 
actually linked to changes of disease activity. The weak 
correlation of the GCF biochemical parameters studied and 
pocket depth were consistent with the results of Haerian et 
al. (1995b) . It may be, that this association was the
result of probing depth measurements taken at one point in 
time being indicative of a past history of periodontal 
disease and not necessarily reflecting active periodontal 
destruction.
There is disagreement in the literature about correlation 
between clinical parameters and biochemical parameters in 
gingival tissue fluid. Kryshtalskyj, Sodek and Ferrier 
(1986), using an experimental dog gingivitis/periodontitis 
model, have shown that an association between the amount of 
collagenase activity and GI, PI, changes of attachment 
level and showed the collagenolytic activities in 
periodontitis sites fluctuated with time, suggesting a 
cyclical pattern.
Villela et al. (1987) demonstrated that the correlation 
between PD and collagenase activity which were measured in 
the same technique in three different group of periodontal 
diseases were different. They found strong correlations 
between pocket depth and collagenase activity on chronic 
adult periodontitis sites, partial correlation in localised 
juvenile periodontitis sites and weak correlation in
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gingivitis sites. Villela et a l . (1987) also showed
partial and strong correlation between gingival index score 
and collagenase activity in localised juvenile 
periodontitis sites and chronic adult periodontitis sites 
respectively, and failed to show any correlation between 
collagenase activity and fluid volume. Teng, Sodek and 
McColloch, (1992) failed to find any correlation between 
clinical parameters and collagenase activity. Gustafsson 
et al. (1992) demonstrated that elastase activity in GCF
showed a moderate correlation with attachment loss and PD, 
whereas the enzyme level did not show any correlation with 
these clinical parameters. Adonogianaki et al. (1993) 
showed that lactoferrin absolute amounts in GCF and 
gingival crevicular washings showed rather strong 
correlations with MGI, PD and GCF volume.
Therefore, it can be inferred that the variation between 
biochemical correlation and clinical parameters may be 
associated with different disease status, local host 
response, periods of rapid connective tissue breakdown, 
activities of enzymes at the time of sampling, different 
laboratory techniques of measuring, as well as different 
methods of GCF sampling. Moreover, the lack of statistical 
analysis always should be considered in terms of outlying 
data which could cause a false positive correlation.
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4.6.5 Comparison of stromelysin and tissue inhibitor
of metalloproteinase (TIMP) in sites which did 
or did not respond to treatment
It is supposed that the level of SL and TIMP in sites which 
failed to respond to treatment showed a different pattern 
of change to those which responded to treatment. However, 
our results did not show this pattern and are consistent 
with the findings of Haerian (1994). The following 
explanation could be provided to explain this observation: 
a) treatments resulted in a reduction in the bacterial 
deposits and removal of the inflamed gingival tissues in 
both groups of the sites as well as an alteration in the 
composition, b) since the antibodies in our study, detected 
total enzyme (latent and active), active enzyme might have 
been lower in sites which gained attachment or had shallow 
pockets than those that showed no attachment gain or had 
deep pockets, as demonstrated by Suomalainen et al. (1992);
c) although these sites had significant improvement in 
clinical conditions, they had no significant attachment 
gain after treatment; d) the pattern that was observed 
might have been caused by different level of treatment.
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4.6.6 Prediction of the outcome of treatment
The clinical and biochemical parameters of the best
responding sites (BRS) and worst responding sites (WRS) are 
discussed separately in order to represent two extremes of 
response. These sites were analysed regardless of type of 
treatment. Comparison between changes of GCF SL and TIMP 
and GCF volume between BRS and WRS revealed that the
changes in the level of SL were higher in BRS compare to
WRS. Thus, it can be concluded that the reduction of the 
enzymes is higher in sites which show clinical improvement.
4.6.6.1 Prediction of treatment response: Using the
pocket depth and the state of bleeding on 
probing
Pocket depth and the state of bleeding on probing, are 
assessed in routine clinical practice to determine the 
response to treatment, thus sites with PD<3.5 and no BOP 
were considered as responding sites. Vanooteghem et al.
(1990) reported the prediction of the treatment outcome, 
using baseline subjective criteria. He showed a maximum 
30% diagnostic accuracy for subjective clinical parameters. 
Our results showed that pre treatment levels of SL and TIMP 
did not to distinguish significantly between the best
responding and worst responding sites. Moreover, the
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baseline levels of SL were lower in responding sites than 
was expected.
However, the inability to predict treatment outcome by PD 
and BOP led us to use the gain in attachment level as an 
indicator of response to treatment.
4.6.6.2 Prediction of treatment response: Using the
attachment level changes as criteria
Due to the chronic and episodic nature of periodontitis and 
the wide range of disease severity affecting different 
teeth within the same subject, clinical parameters show 
insufficient ability to predict disease progression 
(Haffajee et al., 1983a; Jenkins et al. , 1988; Kaldahl et
al., 1990; Badersten, Nilveus & Egelberg, 1990). 
Investigations have been carried out to assess the 
association between attachment loss and biochemical 
components of GCF in order to predict future disease 
activity (Lamster, et al., 1988b; Persson, De Rouen & Page, 
1990). Our results showed that sites which gained clinical 
attachment after therapy had a smaller level of SL at 
baseline compared with sites which lost attachment after 
therapy. However, our results indicated that SL had a 
limited value as a diagnostic marker to differentiate 
between these two clinical categories of sites at a
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statistically significant level. This is in agreement with 
the study of Haerian (1994) .
4.7 Further Study
A recent paper (Golub et al., 1995) reported that 
doxycycline was able to inhibit gelatinase extracted from 
human PMNs whereas the activity of cultured human 
fibroblasts was resistant to this effect until high 
concentrations of the drug were used. The results from our 
study have demonstrated that tetracyclines are able to 
decrease the level of FIB-SL significantly. Since the 
ELISA methodology is unable to distinguish between active 
and latent forms of SL, it can not be established from this 
study whether the effect of tetracyclines on the level of 
SL is on active or latent SL. Therefore, it would be worth 
investigating the effects of locally delivered 
tetracyclines (tetracycline fibre & minocycline gel) on GCF 
MMPs activity using SDS-Page flourography.
Our results showed a tendency toward lower levels of SL in 
best responder sites, although this association was not 
strong. Perhaps a study with a larger number of subjects 
and sites will show a stronger association between clinical 
and biochemical parameters. Moreover, by using a longer 
period of follow up the clinical response could be
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evaluated more realistically, thus, increasing the power of 
statistical tests.
Recent studies demonstrated that the neutrophil 
collagenases have been identified as the major source of 
collagenases in adult periodontitis (Sorsa et al., 1988,
1990, Uitto, Suomalainen & Sorsa, 1990). Our observations 
showed that the detection of FIB-SL in recurrent 
periodontitis sites in maintenance patient was low. This 
tends to confirm the results of the study by Haerian
(1994). Therefore, it would be worth while examining the 
level of these enzymes in the different types of 
periodontal disease.
Sorsa et al. (1995) showed that the level of MMP-1 was 
significantly higher in LJP patients' GCF in comparison to 
AP patients' GCF. Fibroblast type collagenases have been 
shown to be resistant to tetracycline inhibition after 
systemic administration. Therefore, it would be of 
interest to study the efficacy of locally delivered 
tetracyclines as an adjunctive treatment in the control of 
periodontal tissue destruction.
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Abstract
Recent investigations imply that a key mechanism in the pathogenesis of 
periodontal disease may be the ability of oral micro-organisms to induce 
production and /or activation of matrix metalloproteinases (MMPs) in the host 
tissues. It has been suggested that the pharmacologic inhibition of MMP 
activity could play an important role in achieving a desirable outcome in 
periodontal therapy. The efficacy of locally delivered antibiotics on the level of 
gingival crevicular fluid (GCF) stromelysin (SL) and tissue inhibitor of 
metalloproteinases (TIMP) on sites with a history of a poor response to 
mechanical treatment was studied. 52 patients with 4 periodontal pockets >5 
m m  and bleeding on probing were randomised into four groups of 13 patients. 
One group received scaling and root planing alone and the other three groups 
received scaling and root planing plus a locally delivered antimicrobial system. 
These included 25% tetracycline fibre, 2% minocycline gel, and 25% 
metronidazole gel. The GCF samples taken at baseline and 6 weeks after 
treatments were analysed using an enzyme linked immunosorbent assay 
(ELISA). All treatments resulted in significant improvement in clinical 
parameters. The pocket depth reduction was significantly greater in the scaling 
plus tetracycline fibre group than the scaling alone group (p=0.003). GCF SL 
levels significantly decreased after adjunctive tetracycline fibre (paired t-test, 
p=0.020) and minocycline gel (paired t-test, p=0.023) treatments whereas it 
remained almost unchanged in the other two groups. While the GCF TIMP 
level did not change significantly in the scaling and root planing alone group, it 
significantly increased for all three adjunctive antimicrobial treatments (for 
tetracycline fibre p<0.001, minocycline gel p=0.005, metronidazole gel 
p<0.001). The use of adjunctive locally delivered antimicrobial systems, 
particularly, the tetracycline family, may offer an advantage in changing the
1
metalloproteinase profile of the GCF to a one more compatible with periodontal 
health.
INTRODUCTION
Recent investigations imply that a key mechanism in the pathogenesis of 
periodontal disease may be the ability of oral micro-organisms to induce 
production and /or activation of matrix metalloproteinases in the host tissues.1’3 
Stromelysin (SL) is a member of the matrix metalloproteinase family which may 
play a role in chronic inflammatory periodontitis. 4 Extracellular control of these 
enzymes is performed by tissue inhibitor of metalloproteinases (TIMP) 5 and 
during normal tissue turnover, inflammation and healing, levels of MMPs and 
TIMP will change. 6 The effect of treatment on the levels of MMPs and inhibitors 
has been to decrease collagenase activity, 7-9 to decrease the amount of 
collagenase and stromelysin (SL) produced, and to increase the level of 
TIMP.10'11
It has been suggested that the pharmacologic inhibition of MMP activity could 
play an important role in achieving a desirable outcome in periodontal 
therapy.12’16 In addition to antimicrobial effects, tetracyclines have been shown 
to be able to inhibit metalloproteinases (MMPs). However, recent results 
indicate that the inhibition of MMPs by systemic tetracycline depends on the 
drug concentration and type2 as well as the origin of the MMP. 13 Therefore, 
theoretically a great inhibitory effect on MMPs would be expected if higher 
concentrations of drug could be delivered to the site of action. Recently, there 
has been increasing interest in the use of locally delivered antibiotics in order to 
obtain a high concentration of the drug at the target site and to minimise 
potential systemic adverse effects. We therefore sought to investigate the 
effects of locally delivered antibiotics on the amount of fibroblast derived SL and 
TIMP in GCF of sites with advanced periodontal breakdown.
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Materials and Methods 
Selection of subjects and test sites:
52 subjects with adult periodontitis (62% Female; mean age 45 ; range 30-67) 
who had previously been treated with subgingival scaling and root planing, 
were recruited from patients in the Periodontology Unit of Glasgow Dental 
Hospital and School. All study subjects signed an informed consent form and a 
full medical history was recorded. Inclusion criteria required that subjects had 
no history of systemic disease which could influence the course of periodontal 
treatment, and that they were not on any medications such as antibiotic 
therapy, which could influence the manifestations of periodontal disease, within 
the previous 6 months.
Patients selected to take part in the study had at least four periodontal pockets 
equal to or deeper than 5 m m  with bleeding on probing. The patients were 
randomly allocated into four groups of 13 patients each, three of which received 
scaling followed by a locally delivered antibiotic. A total of 208 sites with 
recurrent periodontitis were examined and treated. Two diseased sites were 
excluded for technical reasons, one site lost its tetracycline fibre before the 10 
day placement period finished and in the scaling group a further site could not 
be measured. In order to increase the accuracy of the measurements taken 
and to simplify the harvesting of GCF, the buccal, mesial and anterior sites 
were preferred to the lingual, distal and posterior sites.
Study Visits
Site selection was carried out at the screening visit after a full periodontal 
examination using a PCP-12 probe (Ash, Densply, UK). If the patient fulfilled 
the criteria, an impression was taken, and an acrylic stent fabricated for 
attachment level measurements using the Florida probe (Florida Probe 
Corporation, Florida, USA).
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Oral hygiene instruction was given according to individual needs, but no 
periodontal instrumentation was carried out at the screening visit. 10 days after 
the screening visit baseline measurements were taken. The plaque index (PI) 
of Silness & Loe (1964) 17 was recorded to assess the patient’s oral hygiene, 
the severity of gingival inflammation was measured using the gingival index of 
Lobene et al. (1986). 18 GCF sampling, volume measurements, bleeding on 
probing (BOP) and suppuration were registered. Duplicate measurements of 
pocket depth and attachment level with an acrylic stent were carried out, using 
the electronic pressure sensitive Florida probe, with a constant force of 20 
grams.
At the treatment visits each group received one of the following treatments:
1) Subgingival scaling and root planing under local anaesthesia and the 
application of tetracycline impregnated fibre (Actisite®, ALZA, corporation, Palo 
Alto, CA), into the pocket. The fibre was wrapped loosely around the teeth by 
passing it through the contact points using dental floss or a plastic instrument. 
The pocket was occupied by fibre without creating excessive tension in the soft 
tissues. Cyanoacrylate adhesive was applied to the site and a dressing (Coe- 
Pak, GC America INC. Chicago, IL) was placed. The fibre was removed 10 
days later.
2) Subgingival scaling and root planing plus the application of minocycline 
dental gel (Dentomycin®, Lederle Dental Division, Gosport, Hampshire, 
England), to the pocket until it was overfilled. The excess was removed using 
cotton wool pellets. This application was repeated 14 days and 28 days after 
the initial application.
3) Subgingival scaling and root planing plus the application of metronidazole 
dental gel (Elyzol®, Dumex, Denmark), to the pocket until it was overfilled. The 
excess was removed using cotton wool pellets. The application was repeated 7 
days later.
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4) The control group received subgingival scaling and root planing alone.
42 days post treatment all the baseline measurements were repeated for each 
patient.
During this study other sites received conventional periodontal maintenance 
care.
Sampling method
The site to be sampled was isolated with cotton wool rolls and supragingival 
plaque was carefully removed. The region was dried with a gentle air stream 
and 30s later GCF was collected. A Whatman grade 4 paper strip (2x13 mm) 
was inserted into the crevice until mild resistance was felt and left in situ for 
30s. 19 The sampling method is reliable and causes no significant disturbances 
of the gingival blood vessels20. The fluid volume on the strip was measured 
immediately after sampling with a Periotron 6000 (Harco Electronic, Winnipeg, 
Canada). The jaws of the Periotron were wiped with pure ethanol and then 
dried between readings. Strips were placed in individual sterile micro­
centrifuge tubes and stored at -30° C until further processing was carried out. 
Strips were eluted into 500 pi of incubation buffer at room temperature using a 
rotary mixer. The strips were then discarded and the eluate aliquoted and 
stored at -30° C. These aliquots were subsequently analysed for the 
quantification of SL and TIMP.
Calibration of the Periotron 6000
In order to transform the Periotron digital readings for each paper strip into 
volumes, and also to verify the accuracy of the instrument, the following 
procedure was carried out. Known volumes of PBS plus serum (in equivalent 
volume) were delivered to Whatman grade 4 paper strip with a Hamilton 
microsyringe at a range of volumes (0.05-1 pi) then Periotron readings taken.
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Each measurement was performed 3 times. The mean value for each volume 
was used in a linear regression analysis, from which the slope and intercept 
were used to determine the volumes of GCF collected .
GCF Analysis
All constituents were assayed by means of sandwich enzyme linked 
immunosorbent assays (ELISA), based on a modification of the method of 
Cooksley et al. (1991/ 21 The first antibody, Mac 78 anti-stromelysin for SL 
and Mac 19 anti-TIMP was coated onto a 96-well polystyrene microplate 
(Immulon 4, Dynatech Laboratories, Billinghurst, Sussex, U.K). The 
experimental sample was then added and any antigen present was captured by 
the immobilised antibody. The plate was then incubated with the second 
antibody. Biotinylated Mac 15 antibody and rabbit polyclonal antibody were 
used to reveal TIMP and SL, respectively followed by, in the latter case 
horseradish peroxide (HRP)-conjugated anti-rabbit IgG (donkey) (Jackson). 
The polyclonal and monoclonal antibodies were against both proenzyme, and 
active forms of the enzymes under investigation. The ELISA for TIMP can only 
detect free TIMP.21 All the antibodies were donated by Cell Tech. Ltd. Slough, 
UK. Finally the plate was incubated with Extravidin-Peroxidase (Sigma). 
Visualisation was achieved by incubation with tetramethylbenzidine (TMB) 
(KPL-Dynatech) substrate, and the reaction stopped with 2.5% NaF. The plate 
was read at 630 nm, on a Dynatech MR 5000 plate reader. Serial dilutions of 
standard were run for each individual plate and their optical density (ODs) used 
in a linear regression analysis from which the slope and intercept were used to 
determine the sample concentration of SL and TIMP. Results were expressed 
as pg/30s sample.
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Statistical Analysis
In order to identify the distribution characteristics of the data, it was inspected 
using histograms and it was noted that the data exhibited a markedly skewed 
distribution. Log transformation was successful in producing a normal 
distribution of data within the different groups. The differences in stromelysin 
levels of each subject, between before and after treatment, for each treatment 
group, was subjected to paired t-test. The analysis of covariance (ANCOVA) 
was used on changes of SL and TIMP with the baseline SL or TIMP levels as 
continuous covariates. If a significant difference was found between 
treatments, then the post-hoc comparisons were performed by comparing two 
groups at a time and the probability threshold for statistical significance was 
adjusted to 0.02 using Bonferroni correction22. The Mann-Whitney U test and 
Two sample t-test were used to analyse the baseline levels of SL and TIMP 
respectively between bleeding and non-bleeding sites, and between 
suppurating and non-suppurating sites. Comparisons of SL and TIMP levels at 
sites with different MGI were performed using the Kruskal-Wallis test. Data 
were analysed using Minitab statistical package version 9.2.
RESULTS
Clinical response following the treatments has been reported in a further 
manuscript (Radvar et a i, in press). Briefly, a significant improvement in 
pocket depth, attachment level, bleeding on probing (BOP) and the MGI scores 
occurred in all treatment groups. The tetracycline fibre treatment resulted in a 
significantly greater change in pocket depth than the scaling alone group 
(p=0.003) (Table 1). In addition, the scaling plus tetracycline fibre treatment 
resulted in a greater improvement in the MGI scores than the scaling plus 
minocycline gel treatment (p=0.002), the scaling plus metronidazole gel 
treatment (p=0.007), and the scaling alone treatment (p=0.001). No significant
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difference existed in the MGI scores between other groups. There were no 
significant difference in attachment level changes and BOP changes between 
treatment groups. The GCF volume was reduced siginificantly only the scaling 
plus tetracycline fibre groups. There was no significant changes in the GCF 
volume after other treatments.
The mean GCF level of SL decreased in all antibiotic treated groups and this 
decrease was significant in the tetracycline fibre group (paired t-test, p=0.020) 
and the minocycline gel group (paired t-test, p=0.023) (Table 1). Paired t-test 
demonstrated that the level of GCF TIMP significantly increased in all antibiotic 
treated groups, whereas it decreased in the scaling groups, although not 
significantly (p=0.49) (Table 1). The analysis of covariance (ANCOVA) on the 
baseline SL was used to reduce the error resulting from the variation in the 
baseline. The level of SL at baseline had a significant effect on the SL change 
following treatment (p<0.001), and this effect was positive i.e. the higher the 
baseline SL, the higher the reduction of SL. Treatment also had a significant 
effect on the reduction of SL (p=0.001). Follow-up analysis showed significant 
differences between; i) tetracycline fibre and scaling alone groups (p=0.004); 
and ii) minocycline gel and scaling alone groups (p=0.002) (Table 2).
There was a significant difference in TIMP levels between treatment groups 
(p=0.007). Furthermore, the analysis of TIMP levels revealed that a significant 
difference existed between the minocycline gel and the scaling alone group 
(p=0.018), and also between the metronidazole gel and scaling alone group 
(p=0.001) (Table 3).
The level of SL significantly increased with increasing gingival inflammation 
(p=0.028). No such relationship was observed between gingival inflammation 
and GCF TIMP (p=0.395) (Table 4). The level of SL was higher in sites with 
bleeding on probing (Mean=20.59 pg/pl), than sites with no bleeding on probing
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(Mean=18.57 pg/pl), however the difference was not statistically significant 
(Mann-Whitney U test, p=0.47). TIMP levels were lower in bleeding sites 
(Mean=291.2 pg/pl) when compared with non-bleeding (Mean=322 pg/pl) sites, 
however this was not statistically significant (p=0.395). The level of SL was 
lower in sites with suppuration (Mean=15.69 pg/pl), than sites without 
suppuration (Mean=21.09 pg/pl) but the difference was not significant (Mann- 
Whitney U test, p=0.36). The TIMP level was higher in suppurating sites 
(Mean=381.9 pg/pl) compared with the sites which did not show suppuration 
(Mean=281.1 pg/pl), but this difference was not significant (p=0.12).
DISCUSSION
This paper reports the effects of the local delivery of antibiotics, as an adjunct 
to periodontal treatment, on GCF levels of SL, and TIMP, in patients who had 
previously received periodontal treatment. The clinical results of this 
investigation have been reported by Radvar et al. (1995).23 
Golub et al. (1987) 24 demonstrated that tetracyclines inhibit MMP activity by a 
mechanism independent of their antimicrobial activity. It was shown that the 
systemically administrated tetracycline could inhibit collagenases derived from 
inflammatory sources but inhibition of fibroblast collagenase activity needed 
higher concentrations than could be achieved by this method of delivery.24_25-12" 
13 Therefore, it is hypothesised that locally delivered tetracyclines, due to their 
high local concentrations can inhibit collagenase from both origins. 
Metronidazole appears to reduce the prevalence of Porphyromanas gingivalis 
and spirochetes at active sites in recurrent periodontitis subjects26. In addition, 
the results of Teng et al. (1992) 27 suggest that metronidazole treatment can 
cause the reduction of both active and latent forms of gelatinase. The 
reduction of gelatinase activity is best explained by the antimicrobial effect of
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metronidazole which appears to blunt destructive host immune and 
inflammatory responses.
It has been suggested that SL may act as a marker of stromal cell involvement in 
the process of tissue degradation. 6 Our observation that the mean level of SL 
decreased after antibiotic treatment could be explained by the fact that local 
delivery antibiotics plus scaling and root planing may change the microbial flora. 
This may cause a larger decrease of SL than scaling and root planing alone. 
However, the greatest decrease was observed in the sites treated by 
tetracycline or minocycline delivery systems.
Previous studies have also shown that tetracyclines, in addition to decreasing 
the level of periodontal bacteria, resulting in decrease of MMP activity in the 
gingiva, could decrease the synthesis of pro-MMPs 28-29 and also protect the 
endogenous MMP inhibitors (TIMP-1) and other proteinase inhibitors ( a 1 -  
antitrypsin) 30 from degradation and inactivation by direct and indirect 
mechanisms. However, it cannot be established from this study whether the 
effect of the tetracyclines on the level of SL is direct, or indirect through the 
reduction in microbial challenge which could reduce the microbial proteases 
and inflammatory mediators such as cytokines, both of which could reduce the 
levels of human MMP.
After treatment the level of free TIMP increased. This might be due to a 
reduction in MMPs which would bind to free TIMP. 31-33 The elevation of GCF 
TIMP was higher in the metronidazole group than in the other groups. This 
indicates that the regulation of TIMP is not solely dependent on the MMPs. 
The level of GCF TIMP was significantly elevated in the patients who were 
treated with antimicrobial agents. However it did not significantly change in the 
scaling group. The observation of a greater clinical improvement in all three 
adjunctive antimicrobial treatment groups compared with the scaling and root 
planing alone supports our biochemical findings and suggests that the extent of
10
healing in the patients who received local delivery antibiotics was greater than 
the group who only received scaling and root planing.
It has been suggested that MMP and TIMP may be regulated independently.34 
In conclusion, adjunctive treatment of locally delivered antibiotics, particularly, 
tetracycline fibre and minocycline gel, is able to decrease the production of SL 
in the GCF, although whether this is through direct or indirected mechanisms 
remains unclear. However the correlation between reduced SL and improved 
clinical parameters is confirmatory (Harian et al. 1995) that SL is a marker of 
periodontal health.
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Table 1. Mean differences (baseline - after treatment) of biochemical and 
clinical parameters after therapy in four treatment groups.
Treatment ASL ATIMP Attachment
gain
Pocket depth 
reduction*
S &TC fibre
n
51
mean#
(SEM)
0.11
(0.05)
p**
0.020
mean#
(SEM)
-0.32
(0.07)
p**
<0.001
mean
(SEM)
0.75
(0.12)
p**
<0.001
mean
(SEM)
1.35
(0.17)
p**
<0.001
S & Min gel 52 0.13
(0.06)
0.023 -0.22
(0.08)
0.005 0.40
(0.14)
0.013 0.813
(0.13)
<0.001
S & Met gel 52 0.01
(0.30)
0.730 -0.38
(0.07)
<0.001 0.59
(0.14)
0.001 0.965
(0.18)
<0.001
S 51 -0.01
(0.06)
0.940 +0.05
(0.07)
0.490 0.26
(0.11)
0.032 0.604
(0.14)
<0.001
* The S & TC  showed a significantly greater pocket depth reduction than the S (p= 0.003). 
** Paired t-test, baseline and post-therapy for each treatment
S & TC  fibre= Scaling and Tetracycline fibre 
S & Min gel= Scaling and Minocycline gel 
S & Met gel= Scaling and Metronidazole gel 
S= Scaling alone
# log transformed data
Table 2. Statistical analysis of changes of GCF level of Stromelysin between 
test groups (n=206).
A. Analysis of covariance
Source DF SS MS F P
Baseline SL 1 14.59 14.59 291.03 <0.001
Treatments 3 0.897 0.30 5.97 0.001
Error 47 10.07 0.05
Total 51 25.38
B. Significance
Scaling & Min gel Scaling & Met gel Scaling alone
Scaling & TC fibre 0.658 0.509 0.004
Scaling & Min gel 0.377 0.002
Scaling & Met gel 0.035
TC  fibre= Tetracycline fibre DF= Degree of freedom
Min gel= Minocycline gel SS= sum of square
Met gel= Metronidazole gel M S= Mean square
* Adjusted for baseline level
** After correction the significant threshould was <0.020
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Table 3. Statistical analysis of changes of GCF level of TIMP between test 
groups (n=206).
A. Analysis of covariance
Source DF ss MS F P
Baseline TIMP 1 20.53 20.53 119.25 <0.001
Treatments 3 2.13 0.71 4.13 0.007
Error 201 34.61 0.17
Total 205 60.73
B. Significance
Scaling & TC fibre
Scaling & Min gel Scaling & Met gel
0.503 0.170
Scaling alone
0.036
Scaling & Min gel 
Scaling & Met gel
0.400 0.018
0.001
TC fibre=Tetracycline fibre 
Min gel= Minocycline gel 
Met gel= Metronidazole gel
DF= Degree of freedom  
SS= Sum of square 
M S= Mean square
*  Adjusted for baseline level
** After correction the significant threshould was <0.020
Table 4. Comparison mean (SEM) of GCF SL and TIMP levels for different 
gingival inflammation scores at baseline, using Kruskal-wallis test.
n Stromelysin(pg/30s) TIMP(pg/30s)
MGI=0 6 16.70 (4.12) 295.0 (115)
MGI=1 29 11.50 (1.03) 234.0 (53.2)
MGI=2 112 18.64 (2.28) 326.1 (38.9)
MGI=3 59 28.45 (6.53) 263.4 (38.1)
p value 0.028 0.395
M GI= Modified gingival index
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